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Abstract
Mounting evidence suggests that two major vascular complications of diabetes
mellitus, atherosclerosis and nephropathy, are pathogenically analogous
processes, with atherosclerosis occurring primarily in the macrovasculature and
nephropathy involving the microvasculature. Additionally, several lines of
evidence point to oxidized low-density lipoprotein (oxLDL) as a major participant
in both processes. OxLDL is found deposited in both types of vascular lesions,
and appears to influence several events. It causes influx of macrophages, which
ingest the oxLDL and are transformed into foam cells - a key component of
atherosclerosis and glomerulosclerosis. OxLDL also appears to promote the
proliferation of smooth muscle cells in atherosclerosis and mesangial cells in
glomerulosclerosis; and expansion of the extracellular matrix in both lesions.
Previous work in our laboratory has focused on the immunogenicity of oxLDL,
and we have shown that heterogeneous LDL-containing immune complexes
(LDL-IC), made with human LDL and rabbit LDL-hyperimmune antisera, are
unmatched in their ability to drive the transformation of human monocyte-derived
macrophages into foam cells. Recently, we undertook a three-part endeavor to
better understand the pathogenic role of LDL-IC in microvascular and
macrovascular complications of diabetes. Our goals were to 1) further
characterize oxLDL antibodies that we isolated from serum and immune
complexes; 2) considering the similarities between nephropathy and
atherosclerosis, we wished to determine if LDL-IC are associated with diabetic
nephropathy, as is observed in macrovascular disease; 3) detennine if artificially

xi

prepared homogeneous oxLDL-IC, made with oxLDL and human oxLDL
antibodies, produce similar results in macro phages to those observed with the
use of heterogeneous LDL-IC.
Our characterization of oxLDLantibodies revealed that free and complexed
antibodies, purified from serum and

Ie were predominately of the IgG isotype,

with IgG1 and IgG2 subclasses predominating. Interestingly, we found that the
avidity of oxLDL antibodies isolated from ICs was significantly higher than that of
free oxLDL antibodies. These findings suggest that oxLDL-ICs form stable
circulating complexes and are composed of IgG subclasses that may render
them pro-inflammatory. To investigate the potential association of LDL-IC with
diabetic nephropathYf we compared the concentrations of free oxLDL antibodies,
avidities of free and IC-bound oxLD antibodies, and concentrations of surrogate
markers of LDL-ICs (lC-cholesterol and IC-apolipoprotein 8) in polyethylene
glycol-precipitated les in three nephropathy classes of type 1 diabetic subjects.
Subjects were classified according to their levels of urinary albuminuria, with the
normoalbuminurics demonstrating a urinary albumin excretion (UAE) of

<30mg/day; microalbuminurics had a UAE of 30-300mg/day; and
macroalbuminurics had a UAE of greater than 300mg/day. We observed no
significant difference in serum oxLDL antibody levels between groups, but
identified a significant increase in IC-cholesterol and IC-apoliprotein B in the
microalbuminuric and macroalbuminuric groups when compared to the
normoalbuminuric group. Also, avidity levels of oxLDL isolated from immune
complexes appeared to increase as nephropathy worsened. We interpreted

xii

these data to indicate a positive association between concentrations of LDL-ICs,
and diabetic nephropathy, and that stable immune complexes formed with
antibodies of higher affinity may playa role in the pathogenesis of renal disease
in type 1 diabetes. Since these studies, in conjunction with our previous studies
of heterogeneous LDL-IC-induced foam cell formation in human macrophages
implicated LDL-IC as a potential participant in atherosclerosis and
glomerulosclerosis, but required validation with homogeneous LDL-IC. To meet
this objective, we purified human oxLDL antibodies and synthesized oxLDL-IC by
mixing these antibodies with oxLDL. We then precipitated the oxLDL-IC using
4% polyethylene glycol, and incubated the oxLDL-IC with THP-1 macrophages (a
human monocyte-derived macrophage cell line). After 48 hours incubation, we
extracted the cholesterol from these cells, and measured intracellular cholesterol
ester accumulation. We observed intracellular cholesterol ester accumulation in
cells incubated with oxLDL-IC that exceeded that of cells incubated with oxLDL
alone, and these levels approached that observed in cells incubated with
heterogeneous LDL-IC. These findings validate the continued use of
heterogeneous LDL-IC in studies of foam cell formation. In conclusion, these
findings demonstrate a positive association of diabetic microvascular disease
and LDL-ICs that is reminiscent of that observed between LDL-IC and
macrovascular dtsease. We have shown that homogeneous oxLDL-IC causes
foam cell formation in macrophages, therefore are likely participants in
microvascular (nephropathy) and macrovacular (atherosclerosis) diseases

xiii

processes. Lastly, we have validated the continued use of heterogeneous LDL-

les in studies of macrophage: LDL-IC interactions.
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Chapter I
Introduction
Diabetes mellitus (OM-Attachment 1) has reached epidemic proportions in the
developed nations of the world. This notoriously chronic debilitating disease is
characterized by hyperglycemia and afflicts approximately 16 million people in
the United States (ADA, 1998). All long-term diabetic complications are
essentially the manifestation of diabetic vascular injury, encompassing both
microvascular d~sease (nephropathy, retinopathy, and neuropathy) and
macrovascular disease (atherosclerosis, ischaemic heart disease,
cerebrovascular disease, and peripheral vascular disease) (Breyer, 1992;
Cooper et aI., 1997; Kamanna et ai., 1997; Lloyd et ai., 1996; Lopes-Virella and
Virella, 1998; Maser et aI., 1991; Nathan" 1993; Orchard et at., 1990; Raptis and
Viberti, 2001);' with accelerated and aggressive atherosclerosis being the leading
cause of morbidity and mortality in people with diabetes (Table 1).

Although the pathogenesis of diabetes-related complications is poorly
understood, the relationship between the development of diabetic complications
and poorly controlled hyperglycemia is well established, and is associated with
non-enzymatic glycosylation of proteins, especially collagen, hemoglobin, and
lipoproteins (Brownlee et aI., 1984; Nathan, 1996).

Table 1. Complications of diabetes in the United States (CDC, 1999;
NCHS/CDC, 2000)

Deaths
- Diabetes is the direct cause of an estimated 65,000 deaths among
Americans and is a contributing cause in another 95,000 deaths
. anl')ually.

Heart Disease and Stroke
- People with diabetes have a two to four-fold increase in heart disease
and are two to six times more likely to have a stroke than people who
do not have diabetes.

Kidney Disease
- Diabetes is the single most common cause of end-stage renal
disease (ESRO).
- Thirty to forty percent of those with diabetes develop ESRD.
- Currently over one-third of all patients with ESRD have diabetes and
this number is expected to reach 50% if the current rate of increase
continues.

Blindness
- Diabetes is the leading cause of blindness among adults 20 to 74
years of age.

Amputations
- Diabetes is the underlying cause of the majority of lower limb
amputations.
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· Irrefutable evidence supporting this contention came from the nine-year Diabetes
Control-and Complications Trial (DCeT) reported in 1993. In this large multicenter study, rigid maintenance of near-normal glucose blood levels reduced the
vascular complications of diabetes by more than 50% in 1441 subjects with type
1 diabetes (DCCT/Research/Group, 1993).

The Oxidant Stress Hypothesis
Although compelling evidence points to glycation as a significant participant in
the development of many complications of diabetes, the majority of researchers
and clinicians in the field have well-founded doubts that it alone is directly
responsible for diabetic complications because, quite simply, the structural
changes observed in glycated tissues do not adequately explain all of the clinical
observations (Wolff, 1987). It is widely accepted that the "missing link," in
diabetes-related pathology is answered by a well-supported hypothesis that
looks beyond glycation to one of its known effects: the oxidant stress hypothesis
(Baynes, 1991; Hunt et aI., 1993; Hunt and Wolff, 1991; Miyata et aI., 1999;
Salahudeen et aI., 1997; Wolff, 1987). This hypothesis may well be the missing
piece of the diabetes puzzle, helping explain the diversity and severity of
vascular complications. At the core of this hypothesis, glycation has been
identified as the primary trigger for chronic complications of diabetes.
Hyperglycemia leads to increased glycation of tissues, and a concomitant
increased production of free radical reactive oxygen species (ROS). Being

3

chemically unstable moieties, free radicals are extremely reactive, interacting
directly and indirectly with numerous macromolecules and tissues, causing
oxidant stress-related pathogenesis (Baynes, 1991; Hunt et aI., 1993; Hunt and
Wolff, 1991; Salahudeen at aI., 1997; Wolff,

1987)~

The proposed mechanism by which this takes place is as follows: when protein is
exposed to glucose in vitro, glucose, like other alpha-hydroxyaldehydes, can
enolize. Trace amounts of transition metals, iron and copper, then catalyze the
conversion of the endiol to an endiol radical anion, which is oxidized to a
ketoaldehyde. This "autoxidation" of glucose produces a steady flow of ROS that
contribute to the oxidant stress insult. These free radicals are capable of
causing significant structural and physiological damage by mediating the reaction
of various glucose reactive products (Amadori adduct, etc.) with membrane
proteins, as well as by oxidatively modifying numerous proteins (Baynes, 1991;
Hunt et aI., 1993; Hunt and Wolff, 1991; Salahudeen et aI., 1997; Wolff, 1987)
(Figure 1).

Diabetic Vascular Complications and Low Density Lipoprotein (LDL)
In diabetes research, LDL has received considerable, and well deserved,
attention during the past decade. Not only is it increased in diabetes, but it is
susceptible to glycation and oxidative modification; and its oxidized analog,
oxidized LDL (oxLDL), has been convincingly linked to both microvascular and
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oxidation is catalyzed by transition metals, such as copper, which are either free
in solution or sequestered by protein. Copper attached to the protein may
participate in glucose oxidation, and is involved in oxidative protein alterations
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Amadori pathway is also shown (Hunt et aI., 1993; Hunt and Wolff, 1991).
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macrovascular disease (Esterbauer et aI., 1992; Kreisberg, 1998; Steinberg,
1993; Steinberg et aI., 1989). However, before discussing the potential
pathogenic role of oxLDL in diabetes, it seems pertinent to first summarize some
relevant properties of unmodified, o~ native, LDL (nLDL).

By definition, human nLDL (Figure 2) is the population of lipoproteins that can be
isolated by density-gradient ultracentrifugation within a range of 1.019 to 1.063
g/mL. LDL functions in the blood as the primary supplier/carrier of free and
esterified cholesterol to the peripheral tissues of the body (Olson, 1998). Its
molecules are spherical particles of variable size, measuring 19-25 nM, with
molecular masses of 1.8 to 2.8 million. Each LDL molecule consists of a
hydrophobic lipid core containing 900/0 cholesteryl esters (CE) and 100/0
triglycerides, surrounded by a phospholipid monolayer which contains a massive
protein, apolipoprotein B (apoS) embedded in the outer layer (Myant, 1990).

The biochemical composition of LDL is given in table 2. If one uses 2.5
million as the mean molecular weight of LOL, each sphere is calculated to
contain approximately 1600 molecules of CE and 170 molecules of triglycerides
in the lipophilic core. Surrounding the oily core is a monolayer of approximately
700 phospholipid molecules (primarily phosphatidylcholine with minute amounts
of sphingomyelin and Iysophosphatidylcholine) and 600 molecules of free
cholesterol.
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phospholipid

unesterified (free)
cholesterol

cholesteryl esters (90 %
triglycerides (10 %

)

)

Figure 2. Schematic of a LDL particle. A hydrophobic lipid core consisting of
relatively large quantities of cholesteryl esters (GE) and small quantities of
triglycerides is surrounded a hydrophilic phospholipid monolayer, with a large
protein moiety (apolipoprotein B) embedded.

Table 2. Chemical composition of human LDL
(Esterbauer et aI., 1992).
Component
mean (SO)
Phospholipid (~mol/mg protein)
22.3 (3.0)
Triglyceride (mg/mg protein)
5.6 (2.7)

II Free cholesterol (mg/mg protein)
Cholesteryl ester (mg/mg protein)
Protein (%)
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9.6 (0.7)
42.2 (3.8)

22.0 (1.9)

II

As expected, the polar heads of the phospholipids, which are positioned along
the outermost periphery of the LDL particle, interface with water and enhance
the solubility of LDL in the blood. Also, embedded in the phospholipid monolayer
of LDL is apoS, the largest known single-chain protein, weighing an impressive
550 kDa. Functions of apoB are multifaceted, with it enhancing aqueous
solubility, and appearing to be involved in receptor-mediated endocytosis of LDL
into, cells. Structurally, it is unlikely that apoB sits on the LDL molecule like a hat;
rather experimental data suggest it embraces a large area of the phospholipid
surface of LDL in an octopus-like manner (Esterbauer et aI., 1992).

Extending the discussion of LDL beyond structure to include function, a brief
review of normal intracellular cholesterol metabolism as described by Brown and
Goldstein (Brown and Goldstein, 1984; Brown and Goldstein, 1986) is needed to
help frame the questions addressed in this thesis. As illustrated in figure 3,
intracellular cholesterol is generally derived from two sources: the exogenous
(major) or LDL receptor (LDL-R) pathway, and the endogenous (minor) or 3hydroxy-3-methylglutaryl-coenzyme A (HMG CoAl reductase pathway. Under
normal circumstances, intracellular levels of unesterified (free) cholesterol are
under tight control and maintained within a very narrow range. As intracellular
levels of free cholesterol increase, the following four effects serve as
components of a negative feedback loop: 1) cholesterol is incorporated into the
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cell membranes; 2) synthesis and expression of new LDL receptors is inhibited;
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Figure 3. Normal cholesterol homeostasis in mammalian cells. LDL binds to its
receptor and is ingested by receptor-mediated endocytosis, followed by
internalization and vesicle formation. The vesicle then fuses with a compartment
of uncoupling of receptor and ligand (CURL), where the LDL receptors are
recycled to the cell's surface and LDL is delivered to a lysosome for degradation
of apoB to its constituent amino acids along with cleavage of the esterified
cholesterol to unesterified (free) cholesterol and fatty acids. Intracellular levels of
unesterified cholesterol are normally tightly regulated. Abnormally high levels of
intracellular cholesterol trigger intracellular metabolic events indicated by +
(enhancing) or - (inhibiting). The bold outer lines of LDL indicate the protein
moiety (apoB); the inner spheres indicate lipid. Modified from the description of
Brown and Goldstein, published in 1979 (Brown and Goldstein, 1979).
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3) cholesterol synthesis is curtailed by reducing the synthesis of HMG CoA
reductase; and 4) the activity of acyl CoA:cholesterol acyltr~nsferase (ACAT) is
increased, driving the synthesis of cholesterol esters for storage in the
cytoplasm. These regulatory events are mediated by sterol regulatory element
binding protein, which monitors the free cholesterol concentration in the cell and
adjusts the expression of cholesterol regulatory genes (Chin and Chang, 1981;
Mazzone et aI., 1988; Wang et aI., 1994). The inhibition of LDL receptor
expression and HMG-CoA reductase, in conjunction with enhanced ACAT
activity, effectively curtails internalization of LDL and de novo synthesis of
cholesterol, while enhancing storage of cholesterol esters.

Oxidation, LDL, and Diabetes
Knowledge regarding the mechanisms of oxidation of LDL in vivo is incomplete;
however, what follows is a summary of current thought regarding this process,
and a description of some of the known products of LDL oxidation (Esterbauer et
aI., 1991; Miyata et aI., 1999; Steinbrecher, 1987). Current dogma contends that
oxidation of LDL requires a microenvironment within the arterial wall where LDL
is trapped and sequestered from circulating antioxidants and where the levels of
redox-active metal ions are increased (Lopes-Virella and Virella, 1994b).
Modification may occur directly, as a result of the generation of ROS, followed by
oxidation of amino acids contained within apoB, or indirectly by reactive carbonyl
compounds generated by the autoxidation of carbohydrates, lipids, or amino
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acids (Miyata et aI., 1999) (Figure 4). Autoxidation of carbohydrates produces
reactive carbonyl compounds, such as glyoxal (Wells-Knecht et aI., 1995) and
methylglyoxal·(Ahmed et al., 1997). Lipid peroxidation of polyunsaturated fatty
acids residing in phospholipids and CE in the lipoprotein core are prone to form
highly reactive degradation products, of which, matondialdehyde (MDA) and 4hydroxynonenal (4-HNE)-modified lysine, tyrosine, arginine, and histidine are
best described (Chen et aI., 1992; Esterbauer et aI., 1991; Palinski et aI., 1989).

Oxidation of the hydroxyamino acid, L-serine produces a carbonyl compound
highly reactive with proteins, leading to formation of carboxymethyllysine (CML)
(Anderson et aI., 1997). Each of the reactive fragments described above may, in
turn attach covalently to lysine and histidine residues of apaB, and in the case of
MDAl4-HNE, form advanced lipoxidation end products (ALEs). In addition to the
generation of LDL oxidation-induced adducts, free radical-induced damage of
the protein component of LDL has been shown to cause fragmentation of apoB,
with the fragments subsequently forming high molecular weight aggregates
(Bellamy et aI., 1989) in vitro. In toto, a large variety of LDL neoepitopes are
likely to be generated by these oxidation-induced processes. As noted earlier in
this chapter, an overwhelming body of evidence exists suggesting that diabetes
is associated with increased oxidant stress and enhanced lipid peroxidation
(Baynes, 1991; Hunt et aI., 1993; Hunt and Wolff, 1991; Mooradian, 1991; Rabini
et a I., 1994).
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Following this line of evidence, oxidation of LDL can occur via one or more of
several mechanisms, including: 1) Autoxidation of glucose or Amadori
compounds generates ROS capable of oxidizing LDL (Azevedo et aI., 1988;
Gillery et aL, 1988; Hunt et aI., 1993; Hunt et aI., 1990; Hunt and Wolff, 1991;
Kawamura et aI., 1994; Mullarkey et aI., 1990; Wolff, 1987); 2) glycation of apoB
may generate free radicals, thus initiating oxidation of the LDL particle (Wolff,
1987); 3) nonenzymatic glycation may prolong the half-life of LDL circulating in
the blood, which, in combination with trapping of glycated LDL in the vessel wall
(due to covalent cross-linking to glycated structural proteins) increases the
probability of oxidation (Brownlee et aI., 1984; Kortland et aI., 1992); 4) small,
dense LDL particles are found in increased concentrations in poorly controlled
diabetes, and are more easily oxidized than larger, less dense LDL particles
found in non-diabetic control subjects and subjects with tightly controlled
diabetes (de Graaf et aI., 1991; James and Pometta, 1990; James and Pometta,
1991; Lahdenpera et aI., 1994; Tomkin and Owens, 1994); 5) increased plasma
triglyceride levels, which are commonly observed in poorly controlled diabetes,
are significantly correlated with increased susceptibility of LDL to oxidation in
patients with atherosclerosis (Gin et aI., 2000; Kamanna et aI., 1997; Kreisberg,
1998; Lopes-Virella et aI., 1983; Regenstrom et aI., 1991).

Interestingly, discovery of ox~DL, along with a rapidly growing appreCiation of the
major role post-translationally modified LDL seems to play in atherogenesis,
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occurred during investigations of an apparent paradox. In a series of sentinel
experiments aimed at characterizing the LDL receptor, Brown and -Goldstein
(Brown and Goldstein, 1986; Brown and Goldstein, 1990) made an unexpected
discovery. Their work demonstrated, for the first time, that virtually all cholesterol
in a cell is derived from LOL, and that endocytosis of LDL is receptor-mediated.
As they continued their investigations, they discovered that people who lack
functional LDL receptors (familial hypercholesterolemia) develop atherosclerotic
lesions that are indistinguishable from those found in people with fully functional
LDL receptors. In searching for answers to this apparent. paradox, their elegant
studies demonstrated that the risk of cardiovascular disease was not directly due
to native LOL as many believed. Indeed, it is common knowledge that all cells
require cholesterol supplied by LOL for a variety of functions to include steroid
hormone production and membrane synthesis. However, the abnormal
accumulation of LOL cholesterol in atherosclerotic plaques appeared to be
heavily influenced by post-translational modification of LOL. They discovered
that the accumulation of native LDL in the cytoplasm of cells is a tightly regulated
process, with increasing levels of intracellular cholesterol triggering decreased
expression 'of LDL receptors. However, post-translational modification

.

(acetylation and oxidation, for example) of LDL appeared to negate the stringent
control exerted by the cells' surface LDL receptors, promoting unchecked entry
via scavenger receptors. They observed that when monocyte-derived
macrophages ingested native LOL, lipid-induced negative feedback caused
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down regulation of LDL receptors, and prevented over-accumulation of LDL in
the macrophages. However, when macrophages ingested modified LDL (Le.
QxLDL), negative regulation

appear~d

to be bypassed, causing unregulated

uptake of LDL and the resultant transformation of these macrophages into lipidladen foam cells (FCs) (Brow" and Goldstein, 1990). Adding to this paradox,
Lopes-Virella et a/. discovered that human monocyte-derived macrophages
incubated with oxLDL or LDL-containing immune complexes (LDL-IC) exhibited
an unexpected up regulation of LDL receptors (Lopes-Virella et aI., 1991).
Although these cells had extremely elevated levels of cholesterol, inexplicably
they continued ingesting more lipoprotein than they could excrete, causing
cholesterol to be stored in their cytoplasm in the form of cholesteryl ester
droplets, ultimately transforming them into foam cells and causing cell death.
Interestingly, during these experiments, observations were reported that are very
germane to this dissertation, and will be discussed in more detail shortly: LDLcontaining immune complexes appeared to enhance foam cell formation more
efficiently than modified LDL alone (Gisinger and Lopes-Vi rella, 1992; Griffith et
aI., 1988; Lopes-Virella et aI., 1997a; Lopes-Virella et aI., 1991; Lopes-Virella et
aI., 1997b; Lopes-Virella and Virella, 1992).
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Table 3. Characteristics of OxLDL (Lopes-Virella and Virella, 1996;

Schwartz et aI., 1991; Steinberg, 1993)
-

Chemotactic for monocytes, T lymphocytes

-

Expands extracellular matrix

-

Phagocytized by macrophages, causes foam cell transformation

-

Cytotoxic
Enhances. leukocyte adhesion to the endothelium

17

Modified LDL and LDL-IC are Involved in Complications of Diabetes
Research during the past decade has produced compelling evidence that two
major complications of diabetes, atherosclerosis (primarily a macrovascular
disease) and glomerulosclerosis (primarily a microvascular disease), share some
pathogenic elements; and that oxLDL (Table 3) plays a significant role in both
processes (Diamond, 1991; Hunt et aI., 1993; Hunt and Wolff, 1991; Kamanna et
aI., 1997; Magil, 1999; Moorhead et aI., 1997; Salahudeen et aI., 1997; Witztum,
1994a).

Although atherosclerosis is generally considered a macrovascular disease and
glomerulosclerosis is mostly a microvascular disease, there are striking
similarities between the two disease processes, leading one researcher to
describe glomerulosclerosis as, "glomerular atherosclerosis" (Diamond, 1991;
Moorhead et aI., 1997). It is believed that both processes are initiated by
endothelial insult (due to mechanical, chemical, bacterial, or viral injury), followed

by trapping and oxidation of LOL, monocyte recruitment and activation, smooth
muscle (mesangial) cell proliferation, and fibrous tissue formation (Colwell et aI.,
2001; Lopes-Virella and Virella, 1998; Raptis and Viberti, 2001; Ross, 1999).

Multiple lines of evidence converge on oxLDL, implicating it as a key pathogenic
factor in these vascular diseases. First, oxLDL is present in both atherosclerotic
and glomerulosclerotic lesions, as demonstrated by immunofluorescent staining
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of human histological sections of samples obtained from both types of lesions
with monoclonal 'antibodies to oxLDL (Itabe et aI., 1994; Lee and Kim, 1998;
Magil, 1999). Second, oxLDL appears to have chemotactic properties,
contributing to the accumulation of monocyte-derived macrophages in both
atherosclerotic plaques and glomerulosclerotic lesions (Berliner et aI., 1995;
Berliner et aI., 1990; Kamanna et aI., 1997; Kamanna and Kirschenbaum, 1997;
Kamanna et ai., 1999; Quinn et at, 1987; Quinn et aI., 1985). Third, oxLDL has
been demonstrated to induce proliferation of smooth muscle cells in
atherosclerosis and smooth muscle cell-like mesangial cells in
glomerulosclerosis, and cause the expansion of the extracellular matrix in both
types of lesions (Diamond, 1991; Kamanna et aI., 1997; Moorhead et aI., 1997).
Fourth, oxLDL has been shown to stimulate the transformation of macro phages
into lipid-laden foam cells, and is considered cytotoxic (Ghosh et aI., 1996; Itabe
et aI., 1994; Magil, 1999; Salahudeen et aI., 1997; Steinberg, 1993; Steinbrecher
et aI., 1990). The accumulation of foam cells in lesion sites not only represents a
hallmark of both atherosclerosis and glomerulosclerosis, but mounting evidence
pOints to the central importance of these monocyte-derived macrophages in the
pathogenesis of both lesions (Diamond, 1991; Itabe et aI., 1994; Magil, 1999;
Mitchinson, 1987; Ross, 1999; Witztum, 1994a)

LDL-IC and CE Accumulation in Macrophages
One property of oxLDL, and other modified analogs of LDL, that has received
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considerable attention from our research group, and several others, is the
immunogenicity of modified LDL. Even very minor modifications of LDL are
sufficient to make it antigenic, as reflected by the common presence of oxLDL
autoantibodies in humans (Lopes-Virella and VireUa, 1996; Steinberg and
Witztum, 1999; Steinbrecher et al., 1984a; Yla-Herttuala, 1998). Since it is
reasonable to assume that that these antibodies will bind to their respective
antigens, provided the antigen is present, an area of growing interest is the
potential role of oxLDL and oxLDL-containing immune complexes (Ie) in foam
cell formation, atherogenesis, and glomerulosclerosis (Diamond, 1991; LopesVirella and Virella, 1998; Lopes-Virella et aI., 1999; Magil, 1999). Exploration of
the role of these

Ie in atherosclerosis has led to the observation that oxLDL and

antibodies reacting with modified lipoprotein particles are present in
atheros.clerotic plaques, each having been identified and purified from such
lesions (Palinski and Witztum, 2000; Steinberg et aI., 1989).

In glomerulosclerosis, antibodies to oxLDL have not yet been separated from
glomerulosclerotic lesions, and the potential role of oxLDL-IC in diabetic
glomerulonephritis is unknown. There is, however, evidence suggesting that Ie
playa role in diabetic nephropathy that comes from the common observation of

Ie in the glomeruli of patients with diabetic nephropathy, as indicated by
immunohistochemical staining and the presence of subendothelial high elecron
density deposits (Ainsworth et aI., 1982; Mazzucco et aI., 2002; Osterby et aI.,
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2002; Severgina et aI., 1994; Yoshikawa et aI., 1990). In streptozotocin-induced
diabetic rats, the presence of circulating IC was increased and associated with
IgG deposition in the glomerular mesangium (Abrass, 1984). Additionally,
diabetic glomerulosclerotic lesions have been reported to be exudative, contain
foam celis, oxLDL, immunoglobulins, complement, fibrinogen, and albumin·
(Fioretto and Mauer, 1997, Magil, 1999 #113; Miller and Michael, 1976; Suzuki et
aI., 2001; Velosa et aI., 1976).

Focusing on atherosclerosis, a connection between lesion formation and oxLDLcontaining immune complexes has gained substantial recognition during the last
decade, along with a growing body of evidence suggesting an active participation
of LDL-IC in this process (Klimov et aI., 1988; Lopes-Virella and Virella, 1994a;
Lopes-Virella and Virella, 1998; Mironova et aI., 1997; Salonen et aI., 1992;
Tertov et aI., 1990a; Tertov et aI., 1990b; Yla-Herttuala et ai., 1994). For an
excellent review of the involvement of LDL-IC and atherosclerosis in diabetes,
the reader is referred to the 1997 Diabetes Review article by Lopes-Virella et al.
(Lopes-Virella et aI., 1997b). LDL-IC are believed to be important participants in
the development of atherosclerosis via several avenues (Figure 5).
Macrophages ingest LDL-IC more avidly than uncomplexed LDL via the Fey
receptor I (FcyRI), thus contributing to foam cell formation. The cross-linking of

Fey receptor by LDL-IC, in-tum, induce the release of pro-inflammatory cytokines
(Lopes-Virella et aI., 1997a; Virella et at, 1995).
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Our research group pioneered this area of research, being first to examine the
effects of presentation of LDL:"containing IC on human monocyte-derived
macrophages, subsequently engaging in extensive investigations of this
phenomenon (Gisinger and Lo~es-Virella, 1992; Gisinger et aI., 1991; Griffith et

aI., 1988; Lopes-Virella et aI., 1997a; Lopes-Virella et aI., 1991; Lopes-Virella et
aI., 1997b; Lopes-Virella and Virella, 1996; Lopes-Virella and Virella, 1998).
Research from our group demonstrated that the incubation of monocyte-derived
macro phages with insoluble LDL-IC prepared with heterologous (rabbit) anti-LDL
antibodies and human LDL led to massive (approximately 13-fold) intracellular
accumulation of cholesterol and CE, causing foam cell formation in human
monocyte-derived macrophages (Lopes-Virella et aI., 1991). This set of
experiments further indicated that the accumulation of cholesterol and CE
resulted from a combination of increased uptake and impaired intracellular
metabolism of the LDL ingested as part of an LDL-containing

Ie. The amount of

LDL in human monocyte-derived macrophages after 5 hours incubation with
heterologous LDL-IC was 7-fold higher than that observed in control
macro phages incubated with equal amounts of native LDL. A totally unexpected
finding was the lack of down regulation of the LDL receptor in macrophages with
very high levels of intracellular cholesterol (Griffith et aI., 1988), thus allowing
unregulated uptake of LDL-IC into these lipid-engorged cells via two currently
recognized receptor-mediated avenues: FcyRI, the primary ingestion pathway,
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Modified LDL

~

- -.......

Y J-.Modified lDl Antibodies

LDL.IC

~>'l

Monocyte/Macrophage

Figure 5. LDL-IC and foam cell formation (adapted from (Shunk, 1993).
Antibodies are formed against modified LDL (e.g. oxLDL), and complex with their
antigen, forming LDL-IC. Monocyte/macrophages from the circulation internalize
the LDL-IC primarily through their FcyRI (Lopes-Virella et aI., 1997a). As a
consequence, the cells become activated, release cytokines that activate
endothelial cells, adhere to the endothelium and undergo diapedesis. The CE
from the lipoprotein core of the LDL component of the LDL-IC is hydrolyzed
lysosomally and subsequently re-esterified by ACAT. When these lipidengorged macrophages contain >50% of their total cholesterol as CE, they are,
by definition, foam cells. Foam cells, or their immediate precursors, may
contribute to the progression of the lesion by continuing to secrete various
cytokines which, for example, promote smooth muscle cell proliferation (Ross,
1999), cause endothelial cells to express leukocyte adhesion molecules
(Bevilacqua et aI., 1985; Bevilacqua et aI., 1989; Cavender et aI., 1987), or are
cytotoxiC (Debets et aI., 1990; Lopes-Virella and Virella, 1998; Nakagawara et
aI., 1981; Nathan, 1987). Monocyte/macrophages may also produce oxygen
radicals (Nakagawara et ai., 1981; Nathan, 1987), matrix metalloproteinases
(Huang et aI., 2000; Musson et aI., 1980), and collagenases (Werb et aI., 1980),
which could further exacerbate lesion formation by promoting continued
lipoprotein oxidation, damage to the subendothelial extracellular matrix, and
damage to other cells in the intima.
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and, to a much lesser extent, the LDL receptor (Griffith et aI., 1988; Lopes-Virella
et aI., 1997a). Our research group also showed that the degradation of LDL
bound to IgG was significantly impaired, barely surpassing the degradation of
native LDL (1.09-fold higher), and led to a 200-fold increase in intracellular CE
accumulation (Lopes-Virella et ai., 1991). The characterization of the in vitro
effects of heterologous LDL-IC was complemented by the demonstration that
LDL-IC isolated from human sera had similar properties. Klimov et a/. (Klimov et
al., 1985) demonstrated excessive intracellular cholesterol and CE accumulation
in mouse peritoneal macrophages exposed to LDL-IC isolated from human
serum compared to that of macrophages incubated with LDL alone (Klimov et
aI., 1985). Later, the same investigators reported that LDL-IC isolated from the
blood of patients with atherosclerosis by immobilized staphylococcal A affinity
chromatography caused intracellular accumulation of CE in mouse pericardial
macrophages, and morphological transformation of these cells into foam cells
(Klimov et aI., 1988). Mironova et al. (Mironova et aI., 1997), working in our
laboratory, observed significant CE accumulation in human monocyte-derived
macrophages incubated with human IC isolated from human sera by PEGprecipitation.

LDL-IC and Scavenger Receptor ExpreSSion
As previously mentioned, the experiments with heterologous LDL-IC led us to the
discovery of a paradoxical upregulation of LDL receptor in macrophages
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exposed to LDL-IC containing large amounts of intracellular CEo Our studies of
the binding kinetics of nLDL and macrophages stimulated with LDL-IC showed a
20-fold increase in LDL binding and that this increase in binding was due to an
increase in LDL receptor number (Griffith et aI., 1988). This observation was
confirmed by inhibition of native LDL binding when the receptors were blocked
using monoclonal antibodies against LDL receptors. Furthermore, up regulation
of LDL-receptors was an LDL-IC specific phenomenon. When IC were prepared
with other lipoproteins, including VLDL and HDL, and presented to human
monocyte-derived macrophages, LDL receptor up regulation was not observed.
These data are interpreted as suggesting that the increased expression of LDL
receptors may significantly increase the influx of cholesterol-rich LDL into a cell
that cannot adequately process accumulated cholesterol and that has lost the
ability to down regulate LDL receptor expression.

In a separate series of investigations, Kiener et al. (Kiener et aI., 1995) used a
similar experimental design to implicated scavenger receptors in a similar
function. Using phorbol-myristate acetate (PMA) treated THP-1 cells as a
human monocyte-derived macrophage model, they investigated the effect of
LDL-IC and acetylated LDL on these cells. After presenting the THP-1 cells with
LDL-IC, they exposed the cells to acetylated LDL and were able to show an
increase in intracellular accumulation of acetylated LOL. Following this, they
discovered that the increase was due to a marked increase in scavenger
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receptors, and not due to up regulation of LDL receptors. These observations,
when conjoined--with ours, suggest that LDL-IC transform macrophages into cells
with exaggerated avidity for LDL, rapidly and actively taking up both native and
modified forms of this lipoprotein, via LDL receptors and scavenger receptors.
As a consequence, the cells accumulate cholesterol that they are unable to
process. In summary, LDL.. IC prepared with human LDL and rabbit anti-LDL
antibodies appear to be the most efficient mechanism for the transformation of
human monocyte-derived macrophages into foam cells (Griffith et aI., 1988;
Lopes-Virella et aI., 1991). These observations needed to be confirmed in
experiments where homologous LDL-IC made with modified human LDL and
human anti-LDL antibodies would be incubated with human macrophages.

LDL-IC and Cytokine Release
Not only do LDL-IC cause the up regulation of macrophage LDL receptors and
scavenger receptors, but their ingestion also results in the activation of a variety
of pro-inflammatory macrophage functions. Researchers in our group have
observed that LDL-IC are capable of inducing the synthesis and release of
cytokines (TNF-a and IL-1), and stimulating respiratory burst more efficiently
than any other Ie (Virella et aI., 1995).

Cytokine release, which is a common event observed with Ie-activated
macrophages, is a key step in the inflammation pathway, and has special
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significance in atherogenesis. For example, in endothelial cells, IL-1 has been
shown to stimulate the synthesis and surface expression of procoagulant activity
and platelet activating factor (Bevilacqua et aI., 1984; Breviario et aI., 1988).
Platelet activating factor can interact with granulocytes and directly or indirectly
cause increased vascular permeability (Martin et aI., 1988), and induce a positive
feedback mechanism (Warner et at, 1987) causing even more release of IL-1
from endothelial cells, and induce expression of platelet-derived growth factor AA
(PDGF-AA). PDGF-AA can then trigger fibroblast and smooth muscle cell
proliferation through an autocrine growth-regulating mechanism (Raines et aI.,
1989). In addition to the effects of IL-1, TNF-a is known to induce similar
responses, such as cell membrane expression of procoagulant activity and
production of IL-1 by endothelial cells (Hansson et aI., 1989; Nawroth et aI.,
1986). Both TNF-a and IL-1 can increase endothelial expression of VCAMs,
promoting the adherence of monocytes/macrophages (Beekhuizen and van
Furth, 1993; Cybulsky and Gimbrone, 1991; Pohlman et aI., 1986). Added to
this, foam celis, or their macrophage precursors, may contribute to the
progression of the lesion by secreting various cytokines which act in a variety of
ways, to include promoting smooth muscle cell proliferation (Ross et aI., 1990),
causing endothelial cells to express adhesion molecules (Bevilacqua et aI., 1985;
Bevilacqua et aI., 1989; Cavender et aI., 1987), or be cytotoxic (Debets et aI.,
1990; Lopas-Virella and Virella, 1998; Nakagawara at ai., 1981).
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In glomerulosclerosis, the accumulation of foam cells is also associated with
disease- progression (Klahr -et aI., 1988; Magil, 1999; Rovin and Schreiner, 1991).
Amongst the pathogenetic alterations observed are glomerular remodeling
caused by the release of growth factors (Lovett et aI., 1983; Nathan, 1987), and
glomerular functional changes via the elaboration of cytokines (Schreiner and
Kohan, 1990). Additionally, there is a growing body of evidence implicating
monocyte chemoattractant protein-1 (MCP-1), a specific chemoattractant for
monocytes, in recruiting and activating monocytes/macrophages to the
glomerulus in proliferative glomerular diseases (Banba et aI., 2000; Murphy,
1994; Oppenheim et at, 1991; Ravin et aI., 1992; Santriano et aI., 1993;
Yoshimura and Leonard, 1990).

LDL-IC and Endothelial Cell Damage
Since endothelial insult is considered to be an initiating factor in atherogenesis
and glomerulosclerosis, appreciable research emphasis has focused on
identifying factors that may be involved in it. Though not in the scope of this
thesis, modified lipoproteins have long been implicated in vascular endothelial
cell dysfuntion (Kamanna et aI., 1997; Kamanna et aI., 1999; Lopes-Virella and
Virella, 1996; Ross at aI., 1984). However, in addition to the direct effects of
modified LDL on the endothelium, it is suspected that the activation of
macrophages by insoluble LDL-IC may exert an indirect pathogenic effect on
endothelial cells by generating reactive oxygen species (Virella et aI., 1995) and
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causing free radical damage, while promoting the oxidation of LDL. Yet another
indirect pathogenic action of LDL-IC is through the formation of foam cells.
These lipid-laden monocyte-derived macrophages may add further insult to the
endothelium through the release of matrix metalloproteinases (Huang et aI.,
2000; Nathan, 1987). Additionally, a significant proportion of the damage
induced by these cells is widely attributed to the release of superoxide radicals,
and other reactive oxygen species which can cause increased oxidation of cell
membrane lipids, among other effects (Baynes, 1991; Berliner et aI., 1995;
Boyce et aI., 1989; Colwell et aI., 2001; Hunt et aI., 1993; Hunt and Wolff, 1991;
Virella et aI., 1995; Witztum, 1994a).

LDL-IC and Fc-y Receptors
Having shown that LDL-IC can induce foam cell transformation in human
monocyte-derived macrophages and cause these cells to express
proinflammatory cytokines, two issues remain unanswered. First, how is it that
LDL-IC interact with the macrophage; and second, how do these complexes
become associated with damaged endothelium?

Regarding the interaction of monocyte-derived macrophages and LDL-IC, there
is convincing evidence suggesting that LDL-IC is taken up Fc-y receptors (FcyR). The first report of this came from the studies of Gisinger et a/. (Gisinger et

aI., 1991), where they demonstrated that competing with heat aggregated
gamma globulin (HAGG) effectively blocked CE accumulation in macro phages
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incubated with LDL-IC. Blocking with native LDL and- acetylated LDL had
minimal effect on macrophage CE accumulation, ruling out the significant
participation of LDL receptors and scavenger receptors, respectively.
Subsequent studies have identified FcyRI and FerRl1 as primary participants in
the ingestion of LDL-IC by human monocyte-derived macrophages (LopesVirella et aI., 1997a; Morganelli et ai., 1995). The role of FcyR in the receptormediated uptake of LDL-IC was recently validated, when Shaw et al. reported
that oxLDL-IC prepared with IgG-Fab fragments, which are not recognized by
Fey receptors, were not ingested by macro phages (Shaw et aI., 2001).

Endothelial cells would be an ideal platform for immobilization of circulating LDLIC. Unfortunately, endothelial cells do not normally express FcyR, therefore the
mechanism by which circulating LDL-IC interact with endothelial cells is unknown
(Ryan, 1986). One possibility that fits well with the "response to injury"
hypothesis of atherosclerosis and glomerulosclerosis is that infected or damaged
endothelial cells have been reported to express FcyR (Bengualid et aI., 1990;
Bruggeman and van Dam-Mieras, 1991; Cines et aI., 1982; Friedman, 1984;
Hajjar, 1991; MacCormac and Grundy, 1996; Ryan, 1986). Since many of these
agents have been associated with atherosclerosis, and have been identified in
atherosclerotic lesions, it is not unreasonable to suggest that their presence
could up regulate FcyR in these cells, and thus provide an anchor for soluble
LDL-IC. Alternatively, IgG/lgG-containing IC might bind to cytoskeleton filaments
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exposed on the surface of damaged endothelial cells (Bevilacqua et aI., 1986).
Regardless of the mechanism, once immobilized, an environment would be
created where IgG-containing LDL-IC could interact with, and activate,
macrophages and exacerbate lesion formation (Huang et aI., 2000; Virella et aI.,
1995).

Thesis

Purpos~

Statement

T.he main objective of the research reported in this dissertation was the
verification of the role of human LDL-IC in diabetic nephropathy and foam cell
formation. This investigation was suggested by three main observations. First,
people with diabetes are at increased risk for macrovascular disease
(atherosclerosis), microvascular disease (glomerulosclerosis), and dyslipidemia.
Interestingly, atherosclerosis and glomerulosclerosis are somewhat analogous
processes, sharing several pathogenic characteristics, including the presence of
lipid-engorged monocyte-derived macrophages (foam cells). Second, foam cells
are highly suspect participants, not innocent bystanders, in both processes.
Third, macrophages are transformed into foam cells two ways: endocytosis of
modified LDL (oxLDL, for example); but most efficiently when they ingest LDL-IC.
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Based on a review of the literature and research regarding these observations,
three primary goals were established for this dissertation.

1)

Isolate and characterize oxLDL antibodies that are both free in
circulation (unbound) and associated with LDL, forming soluble
LDL-IC in serum.

2)

Determine if LDL-IC are associated with diabetic
nephropathy/glomerulosclerosis. It has already been shown
that these complexes have macrovascular (atherosclerosis)
connections; we tested the hypothesis that their presence was
also linked to microvascular complications (e.g.
glomerulosclerosis).

3)

Determine if LDL-IC made from human oxLDL and purified
human oxLDL antibodies stimulate foam cell formation. This
goal was essential to validate the results obtained using LDL-IC
prepared from human LDL and rabbit antibodies to human LDL
in previous investigations of the pathogenic significance of LDLIC.
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CHAPTER 2

MATERIALS AND METHODS

Subjects and Samples
This study used blood samples Gollected from 1 ,068 subjects with type 1
diabetes enrolled in the Epidemiology of Diabetes Intervention and
Complications (EDIC) study between May 1997 and May 2000. Blood was
collected by venipuncture at the EDIC clinics, clotted at room temperature for 1
hour and centrifuged to separate serum. EDTA (1 mg/mL) was added to the
serum to prevent LDL oxidation, serum aliquots were immediately stored at 70 o e, and they were shipped monthly to the Medical University of South Carolina
on dry ice. Informed consent was obtained from all the subjects included in the
study. The patients were grouped following American Diabetes Association
criteria (ADA, 2000) based on the average urinary albumin excretion (UAE)
values measured in two determinations performed in a two year period, one prior
to the collection of blood samples, and the other after. Patients excreting <30
mg/24 hr of albumin in the urine were considered normoalbuminuric; those
excreting 30 to 299 mg/24 hr were classified as microalbuminuric, and those
excreting ~300 mg/24 hr were considered macroalbuminuric. Thirty-three
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macroalbuminuric subjects and 29 microalbuminuric were selected for isolation
of circulating

Ie based on their matching with 43 patients with normal

albuminuria for gender, age (within 4 years), and HbA1 c levels (within 1%

,

except in three cases where the HbA1c was greater than 9.5% and the
differences exceeded 1%). A subgroup of 47 patients (22 with normal
albuminuria, 11 with microalbuminuria, and 14 with macroalbuminuria) was
randomly selected from the larger group of 105 patients for detailed
characterization of soluble immune complexes.

Assay of OxLDL Antibodies
The concentration of antibodies to oxLDL was determined by the competitive
enzyme immunoassay previously described (Virella et aI., 1993). The assay is
based on determining the difference in immunoglobulins binding to immobilized
oxLDL between two aliquots of the same serum, one of which has been
absorbed with oxLDL [400

~g/mL

phosphate buffered saline, pH 7.4, containing

1% (w/v) bovine serum albumin (PBS-BSA)], while the other has been incubated
with PBS·BSA alone (unabsorbed aliquot). The enzyme-conjugated antibody
utilized in the assay was a polyvalent anti-lgG antibody that reacts not only with y
heavy chains, but also with

1(

and A light chains, thus measuring antibodies of all

isotypes. The assays were calibrated with a series of dilutions of a human
serum calibrator with known concentrations of oxLDL antibodies (Koskinen et aI.,
1998). The antibody concentrations were calculated from the difference in 0.0.
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(414 nm) between unabsorbed and absorbed aliquots of the tested sera and
were expressed in

~g/mL.

Isolation of Circulating OxLDL Antibodies
OxLDL antibodies were isolated using a previously described affinity
chromatography 'protocol (Mironova et aL, 1996; Virella et aI., 2000). In brief,
freshly isolated LDL was dialyzed against a coupling buffer containing 0.1 mol/L
of NaHC03 and 0.5 mol/L of NaCI (pH 8.3) and incubated overnight on a rocker
at 4°C with CNBr-activated Sepharose 4B (Pharmacia Biotech) prepared in
accordance with the manufacturer's instructions. At the end of this incubation,
free binding sites were blocked with 0.2 mol/L glycine and, after extensive
washing and degassing, the gel suspension was transferred to a
chromatography column and washed thoroughly with PBS, pH 7.4. The column
was then equilibrated with PBS containing 10 J,1mol CuCI2, and the oxidation was
allowed to proceed for 18 hr at 37°C. The oxidation reaction was stopped by
washing the column extensively with PBS containing 300 Jlmol of EDTA and 200
J.lmol of butylated hydroxytoluene (BHT) per liter followed by five washes,
alternating coupling buffer and 0.5 molll sodium acetate + 0.5 M NaCI, pH 4.
Finally, the column was equilibrated with 0.01 molll NaHC03 buffer, pH 8.3.
To isolate anti-oxLDL antibodies from serum samples, 2 ml of serum was
diluted in 8 mL of 0.01 mol/l NaHC03 buffer, pH 8.3 and allowed to diffuse into
the column. After loading, the column was incubated overnight at 4°C, and
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unbound proteins were washed off with the equilibrating buffer. The bound
antibodies were eluted with 0.1-moI/L NaHC03 (pH 8.3) buffer containing 0.5
mollL NaCI. The purified antibodies were dialyzed against PBS, pH 7.4, and
stored at -20°C until analyzed.

Immunoglobulin Isotypes in Purified OxLDL Antibodies
The distribution of immunoglobulin isotypes in the fractions eluted from the
oxLDL column was determined by quantitating IgG, IgM, and IgA by radial
immunodiffusion (RID) using low level RID kits purchased from The Binding Site
Limited, San Diego, CA. The distribution of IgG subclasses in the oxLDL
antibody elution -was also determined by radial immunodiffusion using low level
RID kits also purchased from The Binding Site.

Characterization of Soluble

Ie Precipitated with PEG

A modification of the technique described by Chenais et al. (Chenais et aI.,
1977) was used to preCipitate immune complexes from sera. In brief, a 3 mL
aliquot of serum was gently mixed under constant and gentle stirring with an
equal volume of a freshly prepared and sterilized 8% polyethylene glycol (PEG)
solution in borate buffered saline (88S), pH 8.4, that had been added drop by
drop. The samples, containing a final PEG concentration of 4%, were incubated
overnight at 4°C and then centrifuged at 3000 rpm for 20 min. The supernatant
was discarded and the precipitate was washed once with 14 mL of chilled 40/0
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PEG in BBS, centrifuged again and gently resuspended at 37°C in 3 mL PBS
containing 0.01 % EDTA, pH 7.4. Most studies were carried out with freshly
isolated IC. When necessary, aliquots were stored at -20°C until further testing.

The protein content of PEG precipitates was measured by a modified Lowry
assay (Griffith et aI., 1988). The cholesterol content of the precipitated Ie was
determined by gas chromatography after extraction of the PEG precipitates with
chloroform:methanol (2:1, v/v) (Hara and Radin, 1978). The apolipoprotein B
content of Ie was determined by quantitative immunoelectrophoresis (LopesVirella et aI., 1982).

Isolation of IgG from PEG·Precipitated Immune Complexes
Aliquots of purified IC stored at -20°C were thawed and warmed to 37°C for 20
minutes and resuspended by gentle vortexing. The resuspended IC samples
were loaded onto a protein G column (Pharmacia) and the column was washed
with 0.1 M NaHC03 + 0.5 M NaCI buffer, pH 8.3. This buffer was used because
its ionic strength is sufficient to elute human oxLDL antibodies from an
immobilized oxLDL column, (Mironova et aI., 1996; Virella et aI., 2000) and
therefore, was expected to dissociate any oxLDL-lgG containing IC, allowing the
elution of oxLDL while retaining IgG due to the high avidity interaction between
IgG and protein G. After washing, IgG was eluted using 0.1 M Glycine-HCIbuffer, pH 2.7; and the fractions were immediately neutralized with 1M Tris-HCI-
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buffer, pH 9.0. Neutralized eluates were then dialyzed against PBS overnight,
aliquoted, and stored at -20°C until tested.

IgG Subclass Distribution in OxLDL Antibodies Purified from PEGPrecipitated Immune Complexes
IgG fractions isolated from PEG-precipitated immune complexes, prepared as
previously described, were thawed, diluted to a total volume of 5 mLs with 0.01
molll NaHC03 buffer, pH 8.3 and allowed to diffuse into the oxlDl column.
This column was then incubated overnight at 4°C, and unbound proteins were
washed away with the 0.01 molll NaHC03 (pH 8.3) equilibrating buffer.
Following this step the bound antibodies were eluted with O.1-moI/L NaHC03 (pH
8.3) buffer containing 0.5 mol/L NaCI. The purified antibodies were stored at -

20°C until further testing. The distribution of IgG subclasses in the fractions
eluted from the oxLDL column was determined by quantitating IgG1, IgG2, IgG3,
and IgG4 by radial immunodiffusion (RID) using low level RID kits purchased
from The Binding Site Limited, Birmingham, England. Unfortunately, the initial
step of separating IgG from the immune complexes precluded isolation and
quantitation of IgM and IgA antibodies specific for oxlDL in circulating soluble
immune complexes.

Determination of the Dissociation Constants (Kd) of Purified Antibodies

An estimate of the avidity of each purified antibody eluate was obtained through
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the measurement of ~ (a measure that is inversely proportional to avidity) by
competitive enzyme immunoassay, using a modification of Friguet's method
(Friguet et aI., 1985), as adapted to the characterization of oxLDL antibodies by
Mironova et al. (Mironova et aI., 1996). For this purpose, we coated flatbottomed Immulon type I plates with 7.5 f..Lg of oxLDLper well. Purified oxLDL
antibody was used at a final concentration of 100 )lg/mL. A series of antibody
aliquots was absorbed using concentrations of the apoS component of oxLDL
7

ranging from 7.36 x 10- to 1.15 x 10-8 mol/L, calculated using an estimated
molecular weight of 545kD for apoS.

Absorbed and unabsorbed samples were incubated in oxLDL-coated plates
overnight at 4°C, and after this step the samples were processed as described
for the anti-oxLDL antibody assay. The concentrations of antigen along with the
absorbance values measured in unabsorbed and absorbed samples were used
to construct a plot of vIa vs. v where v corresponds to bound antibody and vIa to
bound antibody/free antigen at equilibrium (Friguet et aL, 1985). The slope of
the plot was used to calculate the

Kct for each sample tested.

LDL Isolation
Blood was collected in EDTA (1 mg/mL) from normal volunteers after 12 hours of
fasting, and plasma was collected after centrifugation. The LDL fraction was
isolated from whole plasma by sequential ultra centrifugation through a KBr
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discontinuous gradient and collected as the fraction floating at a density of 1.019
to 1.063 g/mL using a Beckman L5-50, type 50 rotor, washed by ultra
centrifugation, dialyzed against a 0.15 M NaCI solution containing 1 mM EDTA,
pH 7.4 and stored under nitrogen in the dark (Lopes-Virella et aI., 1982). LDL
preparations were then passed through an Acrodisc filter (0.2 Jlm pore size) in
order to remove aggregates, and a small aliquot taken for determination of
protein concentration by the method of Lowry (Lowry et at, 1951).

LDL Oxidation
LDL was oxidized using the method described by Steinbrecher (Steinbrecher,
1987). To remove residual KBr and EDTA, the freshly isolated LDL was passed
through a PD-10 column (Pharmacia Biotech, Uppsala, Sweden). Phosphatebuffered saline (PBS), pH 7.4, was oxygenated at 2 liters/min for 10 minutes,
and CuCI 2 was added to a final concentration of 10 Jlmol/L for every 300 J.19 of
LDL. The LDL final concentration was adjusted not to exceed 1.5 mg/mL, and
the highest concentration of CUCI2 used was 40J..Lmo1/L when the concentration of
LDL was between 1.2 and 1.5 mg/mL. Oxidation was carried out at 37°C, and to
continuously monitor the degree of oxidation, a 100 J..Lg aliquot of the CuCI2
treated LDL was diluted in 2 mL of PBS and continuously monitored at 37°
spectrophotometrically using a wavelength of 360 nm for excitation and a
wavelength of 430 nm to measure fluorescence emission (Cominacini et aI.,
1991). Four to six hours after fluorescence reached its peak (approximately 18
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hours total time) EDTA and butyl-hydroxytoluene (BHT) was added to the
incubation mixture at final concentrations -of 300 and 200 -,..tmoI/L, respectively to
stop the oxidation process. Copper and BHT were removed from the oxLDL
preparations after termination of the oxidation reaction by overnight dialysis
against 4 liters of a 0.15 mol/L concentration of NaCI containing 300 Ilmoi/L of
EDTA, pH 8.0. After dialysis, oxLDL was filtered through a sterile 0.22-llm-poresize filter to sterilize and remove aggregates and stored at 4°C. The final protein
concentration in each preparation was determined by a Lowry assay (Lowry et
aI., 1951).

Rabbit Immunization and LDL-hyperimmune antibody isolation
For immunization, a narrow density cut (1.030-1.050 g/mL) of unmodified human
LDL was isolated. Each New Zealand White rabbit received a series of 3
immunizations over a six-week period, and were boosted as needed. For the
primary immunization, 1 mg of unmodified LDL was mixed with Complete
Freund's Adjuvant (CFA) to a final concentration of 1mg/mL, and the rabbit was
injected intramuscularly with 0.5 mL LDUCFA at two bilateral sites. Two weeks
later, 1 mg of LDL was mixed with incomplete Freund's Adjuvant (IFA) toa final
concentration of 1mg/mL, and the rabbit was injected intramuscularly with 0.5 mL
LDL/IFA at two bilateral sites in different quadrants than the primary
immunization. Two weeks later, 1mg of LDL was mixed with sterile PBS and the
rabbit received a series of ten-1 OO).1L intradermal immunizations. Blood was
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collected, and the hyperimmune serum was separated and frozen 10-14 days
after the last immunization. Purified IgG. was obtained from human LDL
hyperimmune rabbit serum using Protein G Sepharose (Pharmacia Biotech)
following the manufacturer's instructions.

Preparation of Heterologous Insoluble LDL-Immune Complexes
Insoluble immune complexes were prepared by incubating unmodified human
LDL and rabbit anti-LDL antiserum at a 1:8 dilution in sterile PBS overnight, at
4°C. The concentrations of LDL and anti-LDL antibody used to prepare the
immune complexes were determined by a precipitin curve, constructed by
incubating one milliliter of diluted rabbit anti-LDL antiserum with varying amounts
of LDL (50-500 Ilg) at 4°C overnight. The following day, the protein content of
the insoluble LDL-IC was determined after washing the precipitate three times
with sterile PBS by Lowry assay (Lowry et aI., 1951) calibrated with serial
dilutions of heavily heat-aggregated IgG containing known amounts of IgG.
Using the results of precipitin curves, the ratio of antigen:antibody giving the
greatest amount of precipitate was 200 Jl9 LDL and 1 mL of a 1:8 dilution of our
rabbit anti-LDL antiserum, with the typical yield being 750 J..19 immune complexes
per mL of diluted rabbit anti-LDL antiserum. Insoluble LDL-IC preparations were
sterilized by gamma irradiation.
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Preparation of Human OxLDL-IC [oxLDL-IC(hu)]
Human oxLDL-IC were prepared using human oxLDL and purified human oxLDL
antibodies. To establish the optimal concentrations for the formation of oxLDLIC(hu), we performed a precipitin curve experiment in which 400 mg of purified
human oxLDL antibodies was gently mixed with varying amounts of oxLDL (50500 J.1g/mL) in a fixed volume (1 mL) and incubated overnight at 4°C. The
following day human oxLDL... IC were precipitated using a modification of the
technique described by Chenais et al. (Chenais et at, 1977). In brief, an equal
volume of freshly prepared and sterilized 8% polyethylene glycol (PEG) solution
in borate buffered saline (888), pH 8.4, was added drop by drop under constant
and gentle stirring. The samples, containing the mixtures of antigen and
antibody and a final PEG concentration of 4%, were incubated overnight at 4°C
and then centrifuged at 3000 rpm for 20 min. The supernatant was discarded
and the precipitate was gently resuspended in sterile 0.5 mL PBS containing
0.01 % EDTA, pH 7.4. The protein content of these precipitates was determined
by the method of Lowry (Lowry at aI., 1951). Using the results of precipitin
curves, the ratio of antigen:antibody giving the greatest yield of precipitate was
150 Jl9 oxLDL per 1 mL purified oxLDL antibodies (400 Jlg/mL), with the typical
yield being 250 Jl9 oxLDL-IC. All studies were carried out with freshly isolated
oxLDL-IC, stored no longer than 24 hours at 4°C and sterilized by gamma
irradiation.
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Cell Culture
The human monocytic cell line THP-1 was obtained from the American Type
Culture Collection (ATCC, Rockville, MD). THP-1 celis are well recognized for
their ability to be transformed into macrophage-like cells (Auwerx, 1991).
Compared to other human myeloid cell-lines, such as HL-60, U937, KG-1, or
HEL (Figure 6) cell lines, THP-1 cells are more closely related to monocytes.
Additionally, differentiated THP-1 cells have been
derived macrophages morphologically and

shov~'n

to mimic monocyte-

physiologjca;~y,

rnaking them a model

of choice for studies of monocyte-derived macrophagas (Auwerx, 1991). The
cells were cultured at 37° C in a 50/0 C02 atmosphere in iscove's modified
Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum (FCS)
(Sigma) and antibiotics (penicillin @ 100 U/mL, streptomycin @ 100 )lg/mL,
amphotericin B @ 0.25 )lg/mL). Transformation of the THP-1 cells into
macrophages was performed in the medium described above with the addition of
160 nmol/L phorbol 12-myristate 13-acetate (PMA) for 3 days. After PMA
treatment the medium was aspirated, the adherent celis were washed 3 times
with sterile PBS, and the medium was replaced with a specially formulated
serum free medium (SFM) (Stevenson et aI., 1984) -{or sthi1ulation with varying
concentrations of oxLDL and oxLDL-IC. The SF[vJ Vias G0mposed of IMDM with
the addition of bovine serum albumin (fatty acid free,
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Figure 6. Hematopoietic cell differentiation: outline of the differentiation of
hematopoietic stem cells. Some of the more frequently used myeloid leukemia
cell lines are boxed. CFU=colony forming unit; E=erythrocyte;
GM=granulocyte/monocyte; EO=eosinophil; and mega=megakaryocyte (Auwerx,

1991 ).
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(1 J.lg/mL), and L-phosphatidyl choline (1 Jlg/mL) all from Sigma Chemical
Company (St. Louis, MO): human insulin (0.128 U/mL, Eli Lilly Co., Indianapolis,
IN); and ferrous chloride (0.07 nM, Fisher Scientific, Fairlawn, NJ).

Measurement of Free and Esterified Cholesterol Content
PMA-activated THP-1 cells (1 X 106cells) were incubated for 48 hr with human
oxLDL-IC while oxidized low-density lipoprotein (oxLDL), insoluble oxLDL-IC, and
SFM were used as controls. After incubation, the medium was removed, the
cells were extensively washed with PBS, and the cell monolayer was extracted
with hexane/isopropanol (3:2) (v/v) as previously described (Hara and Radin,
1978). Free and total cholesterol were assayed on a gas chromatograph
equipped with a hydrogen flame ionization detector. A fused silica capillary
column packed with DB 17 was used for chromatographic separation and its
temperature was maintained at 250°C during the separation. Nitrogen was used
as the gas carrier.

To assay total cholesterol, the cellular extracts were evaporated to dryness and
the residue was hydrolyzed by Ishikawa's method (Ishikawa et aI., 1974) as
previously described (Lopes-Virella et aI., 1982). Cholesteryl ester levels were
calculated by subtracting free cholesterol from total cholesterol levels.

~

stigmasterol was used as an internal standard. After the lipid extraction, the cell
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pellet was solubilized with 1 M NaOH, and the protein content determined (Lowry
et aI., 1951).

Statistical Analysis
Results are expressed as mean + standard error, unless stated differently. All
data were analyzed using InStat (GraphPad, San Diego, California) and SAS
(SAS Institute, Inc., version 8, Cary, N.C.) software. ANOVA, with Bonferroni
correctio,n, was used to compare the results of different tests in the three UAE
groups, using the data from patients with normal albuminuria as control. A
paired t-test between two measurements of oxLDL antibody concentrations in
serum against concentrations of the same antibodies isolated from LDL-IC was
conducted. Analysis of covariance (ANOCOVA, Dunnetl-Hsu correction) with
normal albuminuria as control while adjusting for gender, age, HbA 1c among
three UAE groups was performed as indicated. Additional details about
statistical analysis can be found in the footnotes for table 4 and on the legends
for figures 10-13.
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Chapter 3

Results and Discussion

Part 1: Characterization of Oxidized LDL Antibodies

Part 1: Introduction
In recent years, the role of atherogenic lipoproteins in human disease has been
the object of intense research. This research has led to increased attention
focusing on the free radical-mediated oxidative modification of lipoproteins and
their participation in the development of macrovascular disease (atherosclerosis)
and microvascular disease (glomerulosclerosis), two diseases found commonly
in diabetic individuals (Cooper et aI., 1997; Nathan, 1993). In vitro studies have
revealed the apparent susceptibility of LDL to oxidation by endothelial cells,
smooth muscle cells, macrophages, and renal.mesangial cells (Cathcart et aI.,
1985; Morel et aI., 1984; Parthasarathy et aI., 1986; Steinbrecher et aI., 1984b;
Wheeler et aI., 1994); and that oxidized LDL is present in atheromatous and
glomerulosclerotic lesions (Itabe et aI., 1994; Lee and Kim, 1998; Magil, 1999;
Schlondorff, 1993; Yla-Herttuala et aI., 1994). These observations have led to
the belief that oxLDL is somehow involved in both processes.
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Although atherosclerosis is generally recognized as a macrovascular disease
and nephropathy is primarily a microvascular disease, they share several
pathogenic similarities supported by a growing body of evidence suggesting that
atherosclerosis and glomerulosclerosis are indeed analogous pathological
processes (Diamond, 1991; Moorhead et aI., 1997). OxLDL is a suspected
active participant in both processes, and several theories have been proposed to
explain how it appears to contribute to both processes. OxLDL is atherogenic
(Steinberg and Witztum, 1999). It is known to induce chemotaxis and the
recruitment of monocytes into the vascular intima, where monocyte-derived
macrophages avidly ingest it via several types of scavenger receptors, greatly
enhancing intracellular cholesterol accumulation and foam cell formation
(Steinberg, 1993; Yla-Herttuala, 1998), with foam cells being well recognized
hallmarks of both lesions (Guijarro and Keane, 1994; Kamanna et aI., 1997;
Lopes-Virella and Virella, 1998; Magil, 1999; Schwartz et aI., 1991). Additionally,
oxLDL causes endothelial cell dysfunction by upregulating expression of cell
adhesion molecules, effectively enhancing the adhesion/interaction of
monocytes and endothelial cells; and is known to be cytotoxic to cultures of
vascular endothelial cells, glomerular endothelial cells, mesangial cells, and
smooth muscle cells (Berliner et at, 1990; Jeng at aI., 1993; Kamanna et aI.,
1999; Morel et aI., 1983; Shiozawa, 2000; Steinberg and Witztum, 1990).

It is common knowledge that post-translational modification of LDL renders the
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lipoprotein immunogenic, enabling it to interact with the immune system and
generate the formation of antibodies (Steinbrecher et aI., 1984a). In fact,
autoantibodies binding to various epitopes of oxLDL have been described in
humans, rabbits, and mice (Lopes-Virella et aI., 1999; Orchard et aI., 1999;
Orekhov et aI., 1991 b; Palinski et aI., 1994; Palinski et aI., 1989; Parums et aI.,
1990). Interestingly, anti-oxLDL antibodies and LDL-IC have been detected in
human sera with relatively high frequency, and the atherogenic potential of LDLIC is attested to by a large body of experimental data suggesting that incubation
of LDL-IC and human monocyte-derived macrophages severely disrupts the
cell's cholesterol metabolism, leading to massive lipid accumulation in these
macrophages (Gisinger and Lopes-Virella, 1992; Gisinger et aI., 1991; Griffith et
aI., 1988; Klimov et al., 1985; Klimov et aI., 1988; Lopes-Virella et aI., 1991;
Orekhov et aI., 1991 a; Orekhov et aI., 1991 b; Palinski et aI., 1989; Salonen et
aI., 1992; Tertov et aI., 1990a; Virella et aI., 1993). In our laboratory, we have
conclusively shown that co-incubation of LDL-IC and monocyte-derived
macrophages induce foam cell formation more efficiently than any other known
stimulus. Additionally, work from our research group has demonstrated the
ability of LDL-IC to activate macrophages and to cause cytokine release (activate
macrophages), while simultaneously promoting foam cell·formation through a
paradoxical increase in LDL receptors and scavenger receptors (Ghosh et aI.,
1996; Gisinger and Lopes-VireJla, 1992; Lopes-Virella et aI., 1991; Virella et aI.,
1995).
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In light of these observations, it seems logical that there would be keen interest
in determining if oxLDL antibody titers are clinically useful in either reflecting or
predicting the severity index of atherosclerosis and/or glomerulosclerosis.
Surprisingly, studies examining an association of oxLDl antibody titers and
nephropathy are sparse and the results conflicting. While some groups have
reported a positive correlation between oxLDl antibody titers and nephropathy,
others have reported no significant differences in oxLDL antibody levels between
groups with and without nephropathy (Bellazzi et at, 1993; Korpinen et aI., 1997;
Leinonen et aI., 1998). Similar studies in atherosclerosis are not only more
numerous, but have fueled spirited discussions. Many of these studies have
reported elevated autoantibody titers in subjects with increased cardiovascular
risk factors or clinically manifest atherosclerosis, including coronary artery
disease, myocardial infarction, peripheral vascular disease, and hypertension
(Bergmark et aI., 1995; Branch et aI., 1994; Heitzer et aI., 1996; Halvoet et aI.,
1999; Maggi, 1994; Puurunen et aI., 1994). In contrast, an equally impressive
number of studies, including observations from our laboratory, have found no
correlation between the titers of circulating oxLDL antibodies and clinical
indicators of atherosclerosis; and, interestingly, one group even reported a
negative correlation (Festa et aI., 1998; Lopes-Virella et aI., 1999; Maggi, 1994;
Mironova et al., 1997; Orchard et al., 1999; Virella et aI., 1993).

These conflicting data may be due, at least in part, to small sample size,
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sampling demographics, or to differences in screening methodologies. It is
hoped that large-scale clinical studies currently underway and standardization of
oxLDL antibody testing protocols may help resolve these issues. However, the
relationship between oxLDL antibody titers and the severity of atherosclerosis, or
glomerulosclerosis, is undoubtedly complex and may involve the interaction of
one or more of the following scenarios: 1) Accurate determination of the overall
burden of atherosclerosis/glomerulosclerosis is problematic, leaving the real
possibility that non-invasive measurements do not accurately reflect the extent of
disease; 2) Measuring free oxLDL antibody titers may be inaccurate because an
unknown quantity of oxLDL antibodies may be bound to circulating antigens,
forming LDL-IC, as has been reported by our research group in subjects with
diabetes (Lopes-Virella et aI., 1999; Mironova et aI., 2000; Mironova et aI., 1997);
3) OxLDL antibodies may combine with oxLDL in circulation or in tissues other
than arteries and the kidneys, allowing the arteries and kidneys to remain
relatively free of pathological changes in spite of high levels of oxLDL antibody.
In light of these potential pitfalls, and the fact that more than one of the above
processes may be involved, it is surprising that an appreciable number of studies
found a correlation between atherosclerosis, or glomerulosclerosis, and oxLDL
antibody titers at all.

Therefore, we decided to isolate and characterize free and Ie-bound oxLDL
antibodies from human sera to confirm their presence and to attempt to find
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answers to these conflicting reports. This stimulus has led to considerable effort
from our research group directed toward isolating and characterizing human
oxLDL antibodies from serum and oxLDL-IC. The task at hand is ongoing, and
began with the isolation and characterization of oxLDL antibodies from the serum
of eight subjects (Mironova et aI., 1995), and subsequently was expanded to
include the characterization of oxLDL antibodies isolated from serum and

Ie

from 46 subjects. The following results report the fiJldings of this portion of our
study.
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Part 1: Results

Characterization of free serum oxLDL antibodies: oxLDL antibodies were
isolated from the serum of 46 subjects with type 1 diabetes, using a column
containing oxLDL cross-linked to Sepharose, as described in Materials and
Methods. Serum concentrations of oxLDL immunoglobulin isotypes (Figure 7)
and IgG subclasses (Figure 8) were determined by radial immunodiffusion (RID).
The predominant immunoglobulin isotype was IgG (83%), exceeding IgM (140/0)
by a factor of 6. The amount of IgA (30/0) oxlDl antibodies isolated from serum
was minimal. Quantification of IgG subclasses demonstrated a predominance of
IgG1 and IgG3, with IgG1 accounting for 72% of the totallgG levels and IgG3
making up 21 0/0. The average affinity of free oxlDl antibodies was determined
via the dissociation constant (Kd) and found to be 1.13 + 0.13 x 10-8 molll.
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Figure 7. Immunoglobulin isotypes of oxLDL antibodies isolated from
serum of human type 1 diabetic subjects (N=46). Antibodies were
isolated using an oxLDL cross-linked to Sepharose column.
Immunoglobulin isotypes were determined by radial immunodiffusion.
The data in the graph is expressed as mean (mg/L) ± SEM.
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Characterization of oxLDLantibodies isolated from immune complexes:

The isolation of oxLDL antibodies from immune complexes was a complex
multiple-step process that began with the precipitation of soluble immune
complexes present in serum, using a final concentration of 4% PEG. After
precipitating this heterogeneous mixture of immune complexes, we purified
polyclonal IgG from the immune complexes, and then measured anti-oxLDL
activity in the purified IgG. This was not an easy task, and involved a
modification of a technique developed previously in our laboratory (Mironova et
aI., 1997). This technique utilized a protein G column (Pharmacia) to separate
IgG from immune complexes. However, the apparent affinities of oxLDL
antibodies purified in this manner were lower than the affinities of serum (free)
antibodies [unpublished data], and the purified IgG fraction was found to
contained LDl. To overcome this limitation, we capitalized on the observation
that a high salt buffer could disrupt the antigen:antibody interaction of oxLDL-IC,
while having a relatively minimal effect on the binding of IgG to protein G. This
process allowed us to capture immune complex-associated IgG on a protein G
column, dissociate oxlDl, and recover oxLDl-free IgG antibodies for further
testing. Using this protocol, we purified IgG oxLDl antibodies from IC, and
determined their Kd. We found that the avidities of oxLDl IgG antibodies
isolated from immune complexes appeared to be higher than the affinities of free
oxLDL antibodies isolated from serum (0.86 ±O.1 x 10-8 vs. 1.13 ±O.1 x 10-8
molll; p< 0.05). Additionally, we were able to determine the IgG subclass
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distribution of oxLDL antibodies (Figure 9) from the Ie-derived IgG isolates of 9
subject's sera by purifying the oxLDL antibody fraction of IgG, using oxLDL
cross-linked to Sepharose ,column, and found it not significantly different than
that of free oxLDL antibodies isolated from serum.
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Part 1: Summary
Isotypic characterization of free oxLDL antibodies isolated from serum
demonstrated that IgG was the primary isotype, accounting for more than 800/0 of
the isolated oxLDL antibodies, followed by small amounts of IgM and minute
amounts of IgA. The IgG subclass distribution observed in the purified oxLDL
antibodies showed predominance of IgG1 and IgG3, with similar profiles being
observed in oxLDL antibodies isolated from IC. We view this finding as
significant because these IgG subclasses are efficient activators of complement,
and interact with the three types of FcyR; therefore, appear capable of forming
immune complexes with proinflammatory properties (Virella, 2001), and warrant
further investigation. An EIA-based determination of oxLDL avidities showed
that oxLDL antibodies isolated from serum had higher dissociation constants
(Kd) than those observed in oxLDL antibodies isolated from immune complexes
(Kd

=1.13 + 0.13 x 10-8 molll vs. 0.86 + 0.06 x 10-8 mol/L; p<O.05), indicating

that immune complexes are formed with oxLDL antibodies of higher avidity than
that of antibodies that remain in circulation.

Collectively, these findings indicate a possible pathogenic role for oxLDL
antibodies and the oxLDL-IC they help form. Our data strongly suggest that
oxLDL antibodies are predominantly of isotypes and subclasses able to interact
with Fc receptors on phagocytic cells and to activate complement, therefore, are
considered proinflammatory. The observation that the avidity of antibodies
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isolated from soluble Ie exceeds the avidity of free antibodies isolated from
serum suggests that antibodies of oxLDL are of sufficiently high avidity to form
stable IC. These observations, furthermore, indicate that LDL-IC formation may
help explain the discrepant association of oxLDL antibody levels and
atherosclerosis/glomerulosclerosis. It seems reasonable that these

Ie

concentrations may have a stronger'correlation with vascular disease than that
of oxLDL antibody levels alone. Considering the potentially proinflammatory
nature of the antibodies involved in oxLDL-IC formation, further studies
examining the association of oxLDL-IC and vascular disease are needed, as well .
as in vitro investigations examining the potential role of Ie in atherosclerotic and
glomerulosclerotic disease models.
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Part 2: Antioxidized LDL-Containing Immune Complexes in Diabetic
Nephropathy

Part 2: Introduction
It is well known that people with type 1 diabetes are at increased risk of
developing microvascular and macrovascular diseases (Lloyd et aI., 1996; Maser
et aI., 1991; Orchard et aI., 1990; Raskin, 1994), with macrovascular disease
being the leading cause of morbidity and mortality in this group. In toto, these
complications translate into an increased likelihood of ischemic heart disease,
stroke, amputation, kidney failure, and blindness. Interestingly, nephropathy, a
microvascular complication of diabetes, has been shown to accelerate
atherosclerosis in patients with diabetes, and has been identified as a significant
independent riskfactor for macrovascular disease (De Cosmo et aI., 1997;
Ishimura et aI., 2001; Jensen et aI., 1987), suggesting that the two processes are
interrelated. Several hypotheses have been put forward to explain how
nephropathy accelerates the development of macrovascular disease. The most
commonly accepted hypothesis postulates that abnormalities in lipoprotein
metabolism secondary to nephropathy lead to the formation of atherogenic
lipoproteins and, as a consequence, to the accelerated development of
atherosclerosis (Groop et aI., 1996; Hirano, 1999). Some of the better
characterized lipoprotein changes in nephropathy include LDL glycation and
oxidation - the former enhancing the formation of oxidized LDL (oxLDL) as well
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as of advanced glycated end-products (AGE)-LDL (Salahudeen et aI., 1997).
OxLDL and AGE-LDL playa role not only

tn the development of atherosclerosis

but also in the development of nephropathy (Diamond, 1991; Raptis and Viberti,
2001; Witztum, 1994a). Our present study is mainly focused on the role of
oxidized LDL, independently, and as a component of oxLDL-containing immune
complexes (oxLDL-IC), i,n the pathogenesis of diabetic nephropathy.

OxLDL has been del110nstrated in both atherosclerotic plaques and in
glomerulosclerotic lesions, where it appears to be actively involved in lesion
formation. It stimulates monocyte endothelial cell interactions (Berliner et aI.,
1990; Shi et ai., 2000), and acts as a chemoattractant, recruiting macrophages
into atheromatous as well as into glomerulosclerotic lesions (Diamond, 1991;
Kamanna et aI., 1999; Kamanna et aI., 1996; Kaplan and Aviram, 1999; Takaku
et aI., 1999; Witztum, 1994b). After recruitment of macrophages into the lesions,
these cells take up oxLDL and are transformed into foam cells, hallmarks of both
lesions (Itabe et at., 1994; Kamanna et aI., 1997; Lopes-Virella and Virella, 1998;
Magil, 1999). Besides inducing accumulation of foam cells in both
atherosclerotic and glomerulosclerotic lesions, oxLDL induces cell proliferation
(smooth muscle cells in atherosclerotic lesions and mesangial cells in
glomerulosclerosis) and causes expansion of extracellular matrix in both
processes via mechanisms that are both complex and poorly defined (Diamond,
1991; Han and Pak, 1999). Although the exact mechanisms are not known,

63

macrophages undoubtedly occupy a pivotal role in these processes based on the
observation that they' secrete a variety ofcytokines, including transforming
growth factor-J3 which contributes to the expansion of the extracellular matrix via
fibronectin, collagen, and proteoglycan synthesis; and IL-1 ~ which is known to
induce proliferation of vascular smooth muscle cells and mesangial cells (Ku et
aI., 1992; Nathan, 1987; Tesch et aL, 1997).

One property of oxLDL that has attracted considerable attention is its
immunogenicity, as reflected by the formation of oxLDL autoantibodies (LopesVirella and Virella, 1998; Lopes-Virella et aI., 1999; Steinbrecher et aI., 1984a).
Evidence for the involvement of humoral immune factors including
autoantibodies against modified forms of LDL in atherogenesis has been
supported by data from experimental models and clinical studies (Bergmark et
aI., 1995; Griffith et aI., 1988; Kiener et aI., 1995; Klirnovet aI., 1988; LopesVirella et aI., 1991; Lopes-Virella and Virella, 1994a; Mironova et aI., 1997;
Orchard et aI., 1999). In humans, LDL-containing immune complexes (LDL-IC)
are present in the blood of subjects with and without demonstrable vascular
disease (Klimov et aI., 1988; Mironova et aI., 1997; Tertov et aI., 1990a; Tertov et
aI., 1990b), and appear to contribute to atherosclerosis via enhanced intracellular
cholesterol and cholesteryl ester accumulation in macrophages, as well as their
ability to activate macrophages (Klimov et aI., 1988; Lopes-Virella and Virella,
1996; Tertov et aI., 1990a; Tertov et aI., 1990b; Virella et aI., 1995). Studies
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performed in our laboratory (Griffith et aI., 1988; Lopes-Virella et aI., 1991) have
shown that co-incubation of human monocyte-derived macrophages with
heterologous LDL-IC prepared with human LDL and rabbit anti-LDL antibodies is
the most efficient mechanism for inducing foam cell formation. Similar
observations have also been reported using immune complexes isolated from
human serum (Mironova et aI., 2000; Mironova et aI., 1997). -In contrast, studies
examining the possible correlation between the levels of Circulating oxLDL
antibodies and clinical evidence of atherosclerosis have yielded contradictory
and inconclusive results (Bergmark et aI., 1995; Festa et aI., 1998; Klimovet al.,
1988; Lopes-Virella et aI., 1999; Maggi, 1994; Orchard et aI., 1999).
Furthermore, the pathogenic role of oxLDL antibodies has recently been
questioned in two animal studies, wherein the immunization of LDL-receptor
deficient rabbits (Palinski et aI., 1995) and apo-E deficient mice (George et aI.,
1998) with MDA-LDL appeared to have a protective atherogenic effect. The
interpretation of these results to suggest an atherogenic protective role for
humoral immunity to oxLDL in humans (Wick and Xu, 1999) is problematic
because the studies were performed using genetically altered animals, the titers
of antibodies in immunized animals were higher than those measured in
nonimmunized animals, the isotype and avidity of elicited antibodies was not
characterized, and a later study demonstrated that the protective effect of
immunization was not due to oxLDL antibody production (Freigang et aI., 1998).
The lack of correlation between concentrations of circulating antibodies and
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parameters indicative of atherosclerosis. in humans may be explained, at least in
part, by the interference of circulating immune complexes in oxLDL antibody
assays. We have previously reported an inverse correlation between the serum
concentrations of oxLDL antibodies and of LDL-containing immune complexes
(Lopes-Virella et aI., 1999; Mironova et aI., 1997). Thus, the paradoxical inverse
correlation between circulating oxLDL antibodies and vascular disease may
result from the u,nderestimation of oxLDL antibody levels due to the presence of
large concentrations of circulating oxLDL-IC (Lopes-Virella et aI., 1999; Mironova
et aI., 1997). Also, the antibodies responsible for IC formation could be of higher
avidity than those that remain free in serum. As a consequence, the resulting
immune complexes would be relatively stable and more able to cause
inflammatory reactions in sites of formation or deposition. In contrast, the free
circulating antibodies, of lower avidity, may not even playa pathogenic role. The
direct correlation observed between LDL-IC levels and the development of
coronary heart disease reported by us in a previous study certainly supports this
interpretation of the experimental facts (Lopes-Virella et at., 1999).

An attractive hypothesis to explain the better correlation between LDL-IC and
atherosclerosis is that the oxLDL antibodies responsible for

Ie formation are of

higher avidity than those that remain free in serum. As a consequence, the
resulting immune complexes would be relatively stable and more able to cause
inflammatory reactions in sites of formation or deposition. In contrast, the free
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circulating antibodies, of lower avidity, may not even playa pathogenic role.

In light of the hypothesis that atherosclerosis and glomerulosclerosis share
pathogenic factors (Diamond, 1991; Kamanna et aI., 1997), and of our previous
observation of a positive correlation between atherosclerosis and LDL-IC, along
with a negative correlation with free oxLDL antibodies, we decided to investigate
if the levels and characteristics of LDL-IC correlated with diabetic nephropathy.
In the current study, we have tested the hypothesis that nephropathy is
associated with the concentration of circulating immune complexes containing
oxLDL, not with free antibody against oxLDL, that the avidity of antibodies
leading to immune complex formation is higher than the avidity of those
antibodies remaining free in circulation, and that diabetic subjects with increased
albuminuria have oxLDL antibodies in their LDL-IC of higher avidity than patients
without albuminuria. To answer these objectives, we have determined in 105
subjects with type I diabetes, subdivided into 3 groups according to their degree
of albuminuria (an index of nephropathy), the concentration and avidity of free
circulating oxLDL antibodies, as well as the concentration and avidity of these
antibodies in circulating immune complexes. .
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Part 2: Results

The clinical and laboratorial characteristics of the 3 subgroups of subjects
studied are summarized in table 4. The three subgroups were closely matched,
by design, for gender, age, and degree of glycemic control at the beginning of
the study. Significant differences in their lipid profile were observed, as
expected. As shown in table 4, when compared to the subjects with
normoalbuminuria, the subjects with macroalbuminuria had increased levels of
total cholesterol and triglycerides that reached statistical significance, while the
patients with microalbuminuria has significant lower levels of HDL-cholesterol
than those with macroalbuminuria or normoalbuminuria. The levels of circulating
oxLDL antibodies in the 3 subgroups studied were increased in the groups with
microalbuminuria and macroalbuminuria relative to the normoalbuminuric group.
However, the increase did not reach statistical significance (p=O.0885). A trend
analysis comparing UAE with concentrations of circulating oxLDL antibodies also
failed to achieve statistical significance (p=O.0520).
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TABLE 4 - Characteristics of selected study subjects from DCCT/EDIC
cohort
Narmaalbuminuric

Micraalbuminuric

Macroalbuminuric

N

43

29

33

Sex (male/female)

33/10

23/6

25/8

ns

Age (years)

40±8

40±8

40±8

ns

HbA1c(%)

8.7±1.1

9.2±1.3

9.0 ±1.3

ns

Chal (mg/dL)

189±33

188±33

215±40

<0.003

HDL (mg/dL)

56±12

49±10

57±15

<0.05

LDL (mg/dL)

117±30

117±25

130±26

ns

TGL (mg/dL)

81±53

114±69

139±85

Anti-axLDL (mg/dL)

44±5

54±9

72±13

p

<0.002 .

Data are means ± SD. Statistical significance was determined by an ANOVA
among three matched groups with contrast to normal albuminuria as a control
group, testing within-group differences.'
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ns

Measurement of oxLDL antibodies, cholesterol and apolipoprotein B was
performed in immune complexes isolated by precipitation with 3.5% of PEG.
There was no significant difference in the concentrations of oxLDL antibodies in
the PEG precipitates (data not shown). However, as shown in figure 10A, the
mean total cholesterol concentration in PEG precipitates was higher in the
macroalbuminuric (272±20 mg/L) and microalbuminuric (244±20mg/L) groups,
compared to the normoalbuminuric group (204+18 mg/L). The difference
between the cholesterol content of IC in normoalbuminuric and
macroalbuminuric groups reached statistical significance (p<O.03). Additionally,
levels of apolipoprotein B in PEG precipitates showed similar increases in the
macroalbuminuric (134+10 mg/L) and microalbuminuric (110+11 mg/L) groups
compared to the normoalbuminuric group (99+9 mg/L), with the difference
reaching statistical significance when the macroalbuminuric and
normoalbuminuric groups were compared (p<0.03, figure 108). These data
indicate a direct correlation between the levels of LDL-IC and UAE.

70

350
l:J_

(1)-'
~('OCl

DE
(I)
-

(I)

325
300

C(1)

275

0-

250

x
-(1)
LoCo

5E
(1)0

225

0(1)

200

u::J

175

~u

s:::.c
~E

oE
~-

normOalbuminuria
microalbuminuria
macroalbuminuria

ns

T

l:J

p<0.03

T

5· ~

~Cl

oE

~c(l)
-(1)

m~

co.

(i)E
~O

eu
Co(l)
Oc
Co::J

~E

150

. Co

E

c(-

125

160
150
140
130
120
110
100
90
80
7.0

normoalbuminuria
microalbuminuria
macroalbuminuria

P<0.03

T

ns

T

60
50

100

B

A

Figure 10: Total cholesterol (A) and Apolipoprotein 8 (8) levels in
polyethylene glycol-precipitated immune complexes of 105 type l ' diabetic
subjects with varying degrees of nephropathy: 43 subjects had
normoalbuminuria, 29 had microalbuminuria, and 33 subjects had
macroalbuminuria. 0.5 mL serum was precipitated with polyethylene glycol
and cholesterol was extracted using a chloroform:methanol mixture (2:1, v/v).
Cholesterol levels were determined using gas chromatography.
Apolipoprotein B levels were determined using quantitative
immunoelectrophoresis. Results are given in mg/L and data is expressed as
mean ± SEM. Statistical significance was determined by an analysis of
covariance (ANOCOVA) with normal albuminuria as control group when
adjusted for gender, and age, and HbA1c. A Significant difference was
observed between the contents of cholesterol and apolipoprotein B in PEGprecipitated

Ie between the group of patients with macroalbuminuria and the

group of patients with normal levels of urinary albumin.
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The presence of cholesterol and apolipoprotein B in PEG precipi,tates does not
prove that the .precipitated LDL is oxLDL. 'However, we have obtained strong
indirect evidence for the presence of oxLDL in PEG precipitates by isolating IgG
antibodies specific for oxLDL from PEG precipitates. We started by fractionating
PEG precipitates by affinity chromatography using immobilized streptococcal
protein G. Using conventional chromatography conditions that involved washing
unbound proteins from the protein G column with 20 mM sodium phosphate
buffer, pH 7.0, small concentrations of cholesterol are uniformly present in the
IgG fraction eluted with O.2M glycine-HCI buffer, presumably indicating the
retention of Iipoprotein-lgG complexes in the column. The presence of LDL-IC in
the IgG eluates is undesirable because it potentially interferes with the assay of
oxLDL antibody avidity. To avoid this problem, we modified the elution protocol
so that we could dissociate LDL-IC while retaining the absorbed IgG, wash out
the dissociated LDL, and elute antigen-free IgG {table 5}. To this end, we
washed the protein G column with 0.1 M NaHC03 pH 8.3 buffer containing O.5M
NaCI. Under these conditions, the IgG eluted with O.2M glycine-Hel, pH 2.7 was
virtually devoid of cholesterol {cholesterol was undetectable in three out of four
eluates}. The IgG fractions obtained with both protocols contained oxLDL
antibodies, measured by our competitive immunoassay. The recoveries of IgG
and of oxLDL antibody did not differ Significantly with the two different elution
protocols. It must be noted that the recovery of oxLDL antibody was in apparent
excess of the amount loaded in the column, this being at least in part, a
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consequence of the interference of Ie in the assay of oxLDL antibody. Also,
when the concentrations of oxLDL antibodies in serum and PEG precipitated
immune complexes were compared, the levels measured in the IgG fraction
isolated from the PEG precipitates were significantly higher than the levels
measured in serum (Figure 11). The presence of significant amount of oxLDL
antibodies in the purified IgG fraction confirmed our assumption that PEGprecipitated

circ~lating

immune complexes contain oxLDL complexed with its

corresponding antibody in subjects with type 1 diabetes. Interestingly, we
detected small amounts of oxLDL antibodies in protein G washout fractions,
most probably corresponding to immune complexes containing immunoglobulin
isotypes not bound by protein G (primarily IgA and IgM).
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Table 5. Comparison of elution protocols for isolation of IgG from PEG
precipitates of four different individuals. A PEG precipitate was fractionated in a
protein G column in triplicate under two sets of elution conditions.

Original elution protocol a

Modified elution protocol D

480~
480'1
Cholesterol*
Cholesterol*
IgG* .
IgG*
1000'
1000'
60~
ox-LDL Ab*
ox-LDL Ab*
60'
366 ± 40
Cholesterol*
Wash-out
Cholesterol*
443 ± 97
<18
IgG*
IgG*
<18
ox-LOL Ab*
12.3 ± 1.3
ox-LOL Ab*
24.9 ± -0.5
Cholesterol*
2.9 ±2.3
Cholesterol*
Final eluate
0.2 ± 0.3
768 ± 51
IgG*
IgG*
797 ± 110
ox-LDL Ab*
127 ± 61
ox-LDL Ab*
131 ± 41
a Wash-out with 20 mM sodium phosphate buffer, pH 7.0 followed by elution with

Initial load

0.2M glycine-Hel, pH 2.5
b Wash

with 0.1 M NaHC03 pH 8.3 + O.5M NaCI, followed by elution with 0.2M

glycine-HCI, pH 2.5.
* All values are means, expressed in micrograms ± SO (n=4)
1T

Concentrations measured in the original precipitate

Ab = antibody
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Figure 11. OxLDL antibody levels in serum and polyethylene glycol-precipitated
immune complexes of type 1 diabetic subjects (N=47 paired serum and PEG-Ie
samples). OxLDL antibody levels were determined by competitive enzyme
immunoassay in serum and in IgG purified from polyethylene glycol-precipitated
immune complexes using protein G chromatography. The assays were
calibrated with serial dilutions of serum with known concentration of oxLDL
antibody and calculated in mg/L. The data in the graph is expressed as mean ±
SEM. Statistical analysis was performed using a paired t-test of oxidized LDL
antibody concentrations in serum against concentrations of the same antibodies
isolated from immune complexes.
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We then investigated whether or not the avidity of oxLDL antibodies isolated
from sera was comparable in the three subgroups of subjects studied and
whether or not it would differ from the avidity of oxLDL antibodies contained in .
immune complexes. As shown in table 6 the Kd values of oxLDL antibodies
isolated from patient's sera were virtually undistinguishable. A comparison of Kd
values from serum antibodies and antibodies present in immune complexes
showed the later to be of higher avidity (serum antibody Kd = 1.13±O.13 07 x 10-8
mol/L; immune complex antibody Kd

=0.86+0.06 x 10-8 mol/L mol/L; p<0.05).

The average Kd of IgG antibodies isolated from PEG-precipitated

Ie from

patients with UAE equal or greater than 30 mg/24 hr (microalbuminuric and
macroalbuminuric) was lower than the average Kd of IgG antibodies isolated
from PEG-precipitated

Ie from patients with UAE below 30 mg/24 hr

(normoalbuminuric). The differences between the Kd values measured in the
three different groups did not reach statistical significance, but a statistically
significant difference (p<O.05) was observed when the Kd values of the patients
with normoalbuminria were compared with those from a combined group,
including all patients with abnormal albuminuria (Figure 12).
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Table 6. Kd values measured in oxLDL antibodies isolated from serum and IgG
isolated from PEG-precipitated immune complexes

Patient Groups

N

Mean

SE

p

p*

Serum oxLDL
Antibodies Kd
(10-8 mol/L)

Macroalbuminuric
Microalbuminuric
Normoalbuminuric

14
11
22

1.58
1.48
1.51

0.24
0.27
0.19

ns
ns
Reference

ns
ns
Reference

Immune
Complex
oxlDl
Antibodies Kd
{10-8 molll)

Macroalbuminuric
Microalbuminuric
Normoalbuminuric

14
11
22

0.87
0.84
1.13

0.11
0.12
0.08

ns
ns
Reference

ns
ns
Reference

Variable

*p is adjusted for gender, age, and HbA1c.
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Figure 12. OxLDL antibody Kd values measured in IgG fractipns purified from
PEG-precipitated

Ie obtained from the sera of type 1 diabetics with UAE under

30 mg/24 hr (n=22) and equal or greater than 30 mg/24 hr (n=25). IgG was
purified from polyethylene glycol-precipitated immune complexes using protein G
chromatography, and Kd levels were determined by competitive ELISA (see
8

methods). Results are expressed in 10- moles per liter. Statistical analysis was
performed using analysis of covariance while adjusted for gender, age, and
HbA1c.
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Part 2: Discussion
In spite of the prevalence of nephropathy in type 1 diabetes and its associated
morbidity and mortality, the pathogenic mechanisms responsible for its
development· are still poorly understood. However, there'is substantial data
suggesting that the development of nephropathy in type 1 diabetes mimics, from
a pathogenic point of view, that of systemic atherosclerosis (Diamond, 1991; Gin
et aI., 2000; Kamanna et al., 1997; Moorhead et aI., 1997), and that lipids such
as oxLDL are major contributors to the deterioration of renal function (AI-Shebeb
et aI., 1988; Bosmans et aI., 2001; Gin et aI., 2000; Lee and Kim, 1998). The
pathogenic mechanism proposed to explain how hyperlipidemia leads to
nephropathy involves the infiltration of LDL, due to increased capillary
permeability,. into the glomerular mesangium followed by LDL oxidation by
mesangial cells (Wheeler et aI., 1994). As a consequence, there is recruitment
and accumulation of macrophages (Jeng et aI., 1993; Kamanna et aI., 1999;
Kamanna et aI., 1996; Suzuki et ai., 2001), phagocytosis of the oxLDL, and
transformation of these cells into lipid-laden foam cells-a hallmark of diabetic
nephropathy (Magil, 1999). Ultimately, these macrophages become activated,
exacerbating the progression of nephropathy through the release of cytokines,
followed by proliferation of mesangial cells and expansion of the glomerular
extracellular matrix (Moorhead et aI., 1997; Schreiner, 1991; Shiozawa, 2000).
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In contrast to nephropathy, the pathogenic role of modified lipoproteins in
atherosclerosis is well established. It has been investigated from two different
angles: the direct pro-atherogenic effect of oxLDL (Diamond, 1991; Lopes-Virella
and Virella, 1998; Witztum, 1994b) and the effect of the immune complexes
formed as a consequence of the immune response directed against neoepitopes
resulting from lipoprotein modification (Lopes-Virella and Virella, 1998; LopesVirella et aI., 1999). The development of accurate assays for free oxLDL
antibodies (Koskinen et aI., 1998; Lopes-Virella'et aI., 2000; Mironova et aI.,
1997) and design and implementation of techniques for the isolation of oxLDL
antibodies (Lopes-Virella andVirella, 1994a; Virella et aI., 2000) allowed the
investigation of the possible connection between oxLDL antibodies and various
manifestations of atherosclerosis. The majority of isolated oxLDL antibodies
have been characterized as belonging to the IgG isotype, predominantly of the
IgG1 and IgG3 subclasses, and are of moderate to low avidity, two to three logs
lower than the average avidity of polyclonal rabbit anti-apolipoprotein B
antibodies (Virella et aI., 2000).

Support for the atherogenic role of oxLDL antibodies was initially found in some
studies showing a positive correlation between increased Circulating oxLDL
antibody levels and atherosclerotic vascular disease (Bergmark et aI., 1995;
Klimov et aI., 1988; Maggi, 1994), as well as in the isolation of oxLDL and its
corresponding antibodies from atheromatous lesions (Itabe et al., 1994; Palinski
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and Witztum, 2000; Steinberg et aI., 1989). However, our group, as well as
others, has obtained negative data in studies examining the correlation between
circulating oxLDL antibody concentrations and atherosclerosis (Hulthe et aI.,
1998; Virella et al., 1993). Even more perplexing are the reports showing that
the serum concentrations of antibodies to oxLDL are lower in people with
diabetes-related complications than in those without (Festa et aI., 1998; Orchard
et aI., 1990). Palinski et al. raised further questions concerning the pathogenic
role of oxLDL antibodies with a study suggesting that immunization of LDL
receptor deficient rabbits with homologous MDA-LDL had a protective effect
relative to atherogenesis (Palinski et aI., 1995). George et al. (George et aI.,
1998) reported similar observations after immunizing apo-E deficient mice with
MDA-LDL. These observations have been taken out of context to imply that
humoral immunity to oxLDL has general protective effects in humans (Wick and
Xu, 1999); ignoring species differences; that the laboratory animals used in these
experiments were genetically altered; that the titers of antibodies resulting from
deliberate immunization were considerably higher that those measured in nonimmunized animals; and that no attempt was made to compare IgG subclass
distribution or avidity values between spontaneous and elicited antibodies. Also
ignored was the fact that later studies comparing the effects of immunization of
LDL receptor deficient mice with MDA-LDL and native LDL demonstrated that
the protective effect of immunization was unrelated to the production of oxLDL
antibodies (Freigang et aI., 1998).
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While the pathogenic significance of circulating oxLDL antibodies is
questionable, as demonstrated by the contradictory results mentioned above, we
have concentrated our efforts in studying the possible pathogenic role of LDLcontaining IC. The putative role of oxLDL-IC in atherosclerosis is supported by
both in vivo and in vitro data. In vivo, oxLDL and antibodies reacting with
modified lipoprotein particles are known to be components of atherosclerotic
plaques, each having been identified and purified from such lesions, as
mentioned earlier (Palinski and Witztum, 2000; Steinberg et aI., 1989). In vitro
experiments demonstrated that LDL-IC interact with the high avidity Fc receptor
(FerRI) of monocytes and macrophages (Lopes-Virella et aI., 1997a) and are
extremely potent activators of human macrophages, leading to cholesterol ester
accumulation, unregulated expression of LDL receptors, and release of proinflammatory cytokines, metalloproteinases and reactive oxygen species (Griffith
et aI., 1988; Huang et aI., 1999; Kiener et aI., 1995; Klimov et aI., 1988; Tertovet
aI., 1990b; Virella et aI., 1995). This was the impetus for re-examining the
question of the pathogenic role of Ie in atherosclerosis, focusing specifically on
LDL-containing Ie.

Tertovet al. proposed in 1990 that LDL-containing

Ie played a pathogenic role in

atherosclerosis based on in vitro data demonstrating that cholesterol-rich PEG
preCipitates had atherogenic properties when incubated with human
macrophages (Tertov et aI., 1990a). This led the same group to propose that
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LDL-IC could be used as markers of atherosclerosis (Orekhov et aI., 1991 a).
Later publications on the same topic had conflicting conclusions. Boullier et aI.,
using an enzyme immunoassay for LDL-IC detection, reported that LDL-IC were
not increased in subjects suffering from coronary atherosclerosis (Boullier et aI.,
1995). In contrast,- Ahmed et aI., using a similar assay, reported a higher
prevalence of circulating IC in diabetic patients with vascular complications
(Ahmed et aI., 1999). Our initial studies failed to clarify the issue, when we
proved that atherogenic Ie could be isolated not only from the sera of subjects
with diabetes, but also from the sera of normal controls (Mironova et aI., 1997).
However, data from a prospective study of a group of type I diabetic subjects
demonstrated that LDL-IC were risk factors for coronary heart disease in these
patients (Lopes-Virella et aI., 1999; Orchard et aI., 1999).

A suspected correlation between ox LDL antibodies and diabetic nephropathy
was first investigated by Korpinen et aI., but they found no association between
serum levels of oxLDL antibodies and diabetic nephropathy or nephropathyrelated macroangiopathy (Korpinen et aI., 1997). In our current study we were
also unable to show a significant correlation between free, circulating oxLDL
antibody levels and proteinuria. However, when we focused our attention in
LDL-IC levels we obtained evidence supporting the involvement of LDL-IC as
pathogenic factors in diabetic nephropathy, as reflected by abnormal
albuminuria. Significantly higher levels of cholesterol and apolipoprotein B were
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detected in the PEG precipitates of subjects with abnormal UAE, particularly
those with macr9albuminuria.But more significantly, we were able to purify
antigen-free IgG from PEG precipitates and demonstrate that it contained oxLDL
antibodies, and that these antibodies were of higher avidity than free, circulating
oxLDL antibodies. Furthermore, we have shown that the avidity of antibodies
contained in PEG precipitates was significantly higher in subjects with abnormal
UAE values. The nature of the LDL molecules found in the PEG precipitates
could not be established directly by the performed assays of cholesterol and
Apo-B. No fully satisfactory. method for specific assay of oxLDL in small
samples, such as PEG precipitates, is available. Attempts to develop
immunoassays have not been successful because of the lack of adequate
commercially available polyclonal or monoclonal antibodies. Chemical assays,
on the other hand, require considerable quantities of lipoprotein that cannot be
obtained from clinical samples. However, the demonstration of oxLDL antibodies
in the PEG precipitates strongly supports the hypothesis that the PEGprecipitable IC contain oxLDL.

This, to our knowledge, is the first report showing evidence that supports a
pathogenic role for oxLDL-containing

Ie in diabetic nephropathy..

Our data

further suggest that the pathogenic potential of oxLDL IC is directly related to
oxLDL antibody avidity . The correlation between antibody pathogenicity and
avidity agrees with classical observations published by Winfield et al. who
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demonstrated in the late 1970s that ,the avidity of antibodies eluted from
deposited Ie was significantly higher than the avidity of circulating antibodies of
the same specificity (Winfield et aI., 1977). The fact that Ie containing IgG
oxLDL antibodies of higher avidity predominated in patients with micro and
macroalbuminuria is likely to be a reflection of the fact that as the antibody
avidity increases, the ability to form stable complexes is enhanced~ The
formation of stable IC involving biologically active antibodies (lgG1 and IgG3
particularly) is, in turn, a requirement for the activation of pro-inflammatory
mechanisms (Theofilopoulos and Dixon, 1979). From previous work conducted
in our laboratory we know that oxLDL antibodies are predominantly of the IgG1
and IgG3 isotypes (Mironova et aI., 1996), able to activate the classical pathway
of the complement system and to engage all known types-of Fey receptors
(Virella and Wang, 1998).

The process by which oxLDL-IC mediate glomerular damage is not clear.
OxLDL has been shown to induce proliferation of mesangial cells, a prominent
feature of diabetic nephropathy (Moorhead et aI., 1997), and cause the
expansion of the extracellular matrix (Diamond, 1991; French et al., 1967). In
tum, mesangial cells have been shown to oxidize LDL (Wheeler et at, 1994). In
the case of human macrophages, the higher atherogenic potential of ox-LDL Ie
relative to free oxLDL seems to be related to the engagement of FcyRI by the Ie
(Lopes-VirelJa et aI., 1997a). Human mesangial cells have been reported to
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express this same receptor after activation by interferon-y (Uciechowski et aI.,
1998).. It remains to be determined if uptake of oxLDL

Ie through this receptor

can activate mesangial cells to the same extent as macrophages. If it does, the
question of the in vivo cellular source of interferon-y will arise. As in the
pathogenesis of large vessel atherosclerosis, it is likely that a variety of immune
cells·are involved in the process. Activated T cells reacting with oxLDL and hsp50-derived epitopes have been detected in atheromatous lesions (Stemme et aI.,
1995). A similar involvement at the glomerular level could account for the
release of interferon-y and mesangial cell activation. These and many other
questions will have to be explored to reach a better understanding of the
pathogenic role of oxLDL-IC in diabetic nephropathy.
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Part 3: Effects of Homologous Human OxLDL·Containing Immune
Complexes

Ie on Human Macrophage-like Cell Line, THP-1 Cells

Part 3: Introduction
During the last 20 years, research in cardiovascular disease has accumulated a
large body of evidence suggesting an important role for low density lipoproteincontaining immune complexes (LDL-IC) in the pathogenesis of atherosclerosis,
as reviewed by Lopes-Virella and Virella in 1998 (Lopes-Virella and Virella,
1998). Supporting the proatherogenic role of LDL-IC are reported observations
that atherosclerotic lesions contain both oxLDL and LDL antibodies (Itabe et at,
1994; Palinski and Witztum, 2000; Steinberg et al., 1989; Steinbrecher et aI.,
1990). Epidemiological data has been obtained suggesting that soluble LDL-IC
are detected in the serum of subjects with coronary artery disease (CAD) at
levels significantly higher than subjects without CAD (Lopes-Virella et aI., 1999;
Orchard et aI., 1999; Orekhov et aI., 1991a; Tertov et ai., 1990a), with data
obtained' in a 'prospective study involving diabetic subjects suggesting that
increased levels of LDL-IC were predictive of CAD (Lopes-Virella et at, 1999;
Orchard et aI., 1999). Additionally, soluble LDL-IC isolated from the serum of
subjects with coronary heart disease, by chromatography using immobilized
staphylococcal protein A or precipitation with polyethylene glycol, have been
shown to be atherogenic, as indicated by their ability to induce intracellular
accumulation of cholesterol and cholesteryl ester (CE) in pericardial
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macrophages and smooth muscle cells (Klimov et aI., 1988; Tertov et aI.,
1990a).

Transformation of human monocyte-derived macro phages into lipid-laden foam
cells is a key manifestation of the atherosclerosis process (Gerrity, 1981;
Schaffner et aI., 1980). Therefore, it should come as no surprise that the role of
LDL-IC in foam cell formation has received significant attention. Beginning in the
1980s, researchers in our group began investigating the effects of LDL-IC on
human monocyte-derived macrophages, and later on, we extended these
observations to the human monocytic cell line THP-1 , a widely used human
macrophage model (Auwerx, 1991; Lopes-Virella et aI., 1997a). Numerous
studies in our laboratory have shown that co-incubation of human monocytederived macrophages with LDL-IC prepared with human native LDL and rabbit
anti-human LDL antibodies cause intracellular CE accumulation, and subsequent
foam cell formation more efficiently than any other known mechanism of foam
cell formation (Griffith et ai., 1988; Lopes-Virella et aI., 1991). The massive
intracellular increase in cholesterol and CE accumulation and impaired
cholesterol homeostasis observed in THP-1 cells incubated with LDL-IC mirror
the effects of LDL-IC on human monocyte-derived macrophages, substantiating
the use of this cell line as a model of human monocyte-derived macrophages
(Huang et aI., 1997).
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Substantial data has been accumulated, suggesting that the intracellular
accumulation of cholesterol and CE in macrophages incubated with LDL-IC, and
resultant foam cell formation, is the result of a complex series of actions
triggered by LDL-IC. For example, the results of studies conducted in our
laboratory indicate that the massive CE accumulation is due to a combination of
increased uptake and impaired intracellular metabolism of the ingested LDL
component of the LDL-IC (Lopes-VirelJa et aI., 1991). We have demonstrated
that the amount of LDL taken up by human macrophages at the end of 5 hours is
an impressive 7-fold higher when the LDL is complexed with antibody than when
cells are incubated with native LDL alone. In addition to enhanced ingestion of
LDL-IC, we have also observed that there is a delay in degradation of LDL when
it is complexed with IgG. Pulse-chase experiments have shown that degradation
of IC-complexed LDL takes up to 48 hours, and that as the LDL is hydrolyzed;
cholesterol is released and re-esterified by ACAT leading to intracellular
cholesterol and CE accumulation (Lopes-Virella et aI., 1991). Taken together,
these observations demonstrate the ability of LDL-IC to cause intracellular lipid
accumulation by at least two mechanisms: increased lipid ingestion, and
decreased lipid clearance.

Thus, there is solid evidence suggesting a role for LDL-IC in the pathogenesis of
atherosclerosis. Unfortunately, the vast majority of these studies have been
performed using LDL-IC prepared with human LDL and rabbit hyper-immune
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anti-sera against human LDL, or an ill-defined heterogeneous mix of human
LDL-containing Ie and other Ie isolated from,human sera by PEG precipitation.
The experimental designs have left unresolved the question of whether LDL-IC
prepared with heterologous antibodies of much higher avidity than the naturally
occurring human antibodies truly represent the effect of homologous LDL-IC on
human macrophages. There is also some uncertainty regarding what types of
LDL-IC isolated from human serum are responsible for foam cell formation in
macrophages. In this paper, we report the results of a series of experiments
supporting our contention that homologous LDL-IC prepared with human oxLDL
and human antibodies to oxLDL (oxLDL-IC) are metabolized by human
macrophages similarly to heterologous LDL-IC prepared with human LDL and
hyperimmune rabbit anti-human LDL serum. We believe that these data prove
that human oxLDL autoantibodies can form atherogenic LDL-IC and validates
the continued use of LDL-IC prepared with human LDL and heterologous antiLDL antibodies to study the interactions of human monocyte-derived
macro phages and LDL-IC.
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Part 3: Results
The protocol developed for preparing and isolating homologous human oxLDL-IC
involved multiple steps. We began by isolating oxLDL antibodies from human
sera, using a column containing oxLDL cross-linked to Sepharose. The eluted
antibodies were then dialyzed and incubated overnight at 4°C with varying
concentrations of copper-oxidized LDL to allow formation of oxLDL-IC. Unlike
the insolu~le immune complexes formed with heterogeneous mixtures of human
LDL and LDL-hyperimmune rabbit sera, which are relatively simple to make and
purify, oxLDL-IC formed with human oxLDL and purified human oxLDL
antibodies are soluble complexes, and cannot be isolated by simple
centrifugation. To overcome this obstacle, we first prepared soluble oxLDL-IC by
incubating oxLDL with purified human oxLDL antibodies overnight at 4°C. We
then added polyethylene glycol (PEG), at a final concentration of 4%, to the
antigen-antibody mixture to preCipitate the soluble immune complexes. After
overnight incubation at 4°C, we obtained oxLDL-IC precipitates that were
isolated by centrifugation, reconstituted in PBS, and subsequently analyzed.
Figure 13 shows the results of a precipitation curve prepared with different
antigen-antibody ratios and identical PEG concentrations (4%). The curve
indicates that optimal yields of oxLDL-IC complexes are obtained when 150 I1g
oxLDL is mixed with 400 J..L91 of purified oxLDL antibodies.
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Figure 13. Homologous human oxLDL-IC precipitation curve.
Variable concentrations of oxLDL isolated from human serum were
added to 1 mL of purified human oxLDL antibody aliquots
containing 400f,lg/mL of protein. After overnight incubation,
addition of 40/0 PEG, and a second overnight incubation,
precipitates were separated by centrifugation, and protein
concentration was determined in resuspended precipitates by the
Lowry method (Lowry et aI., 1951).
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In order to rule out nonspecific precipitation of proteins by PEG, we next
designed an experiment to compare the protein concentrations precipitated from
oxLDL alone, oxLDL + an irrelevant antibody (rabbit anti-Rho), oxLDL + human
oxLDL antibody, and oxLDL + LDL-hyperimmune rabbit antibody_ In this
experiment, oxLDL alone and oxLDL + the irrelevant antibody served as negative
controls, while oxLDL + LDL-hyperimmune rabbit antibody served as a positive
control. In all conditions, both theoxLDL concentration and antibody
concentration were kept constant, at 150 Jl9/mL and 400 Jlg/mL, respectively, as
determined by the Lowry method. The results are graphically represented in
figure 14, and demonstrate that oxLDL-IC are formed when oxLDL is mixed with
purified oxLDL antibodies, and that PEG precipitates minimal amounts of
uncomplexed proteins/lipoproteins.
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Figure 14. Specificity of oxLDL-IC precipitation by 4% PEG. Copperoxidized LDL alone, oxLDL plus anti-Rho '(irrelevant) antibodies, oxLDL plus
purified human oxLDL antibodies, and oxLDL plus purified hyperimmune
rabbit IgG was precipitated with 4% PEG, and precipitate concentrations
were compared by protein Lowry. All conditions used a final volume of 1 mL
in PBS, 150Jlg oxLDL, and 400 fJ.9 of the antibody indicated.
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Having successfully established a method to reproducibly prepare and purify
homologous human oxLDL-IC, we then carried out experiments to determine if
these complexes would alter cholesterol metabolism, resulting in cholesterol and
cholesteryl ester accumulation in macrophages, as· has been observed in
macrophages incubated with LDL-IC prepared with human LDL and
hyperimmune rabbit anti-human LDL antibodies. To this end, we transformed
monocytic THP-1 cells to macro phages by treatment with 160 nmollL phorbol12myristate 13-acetate (PMA) for 3 days, and incubated the THP-1 macrophagelike cells with varying concentrations of human homologous oxLDL-IC or oxLDL
alone. During incubation of these macrophages with free oxLDL or with oxLDLIC, it was found that the majority of concentrations studied (50-200 mg
oxLDL/oxLDL-IC per mL) caused an increase in total cholesterol (Figure 15A).
And we observed that the increase in both components of total cholesterol (free
cholesterol and eE) was much more pronounced in cells incubated with oxLDL-

Ie, compared to those incubated with free oxLDL (Figure 15A). Beginning at 50
Jlg/mL, intracellular CE accumulation in cells incubated with oxLDL-IC was

increased more than 2-fold higher than cells incubated with free oxLDL alone.
Figure 158, shows that the accumulation of intracellular CE occurred in a dosedependent manner, indicating the ability of oxLDL-IC to dramatically alter
cholesterol metabolism and lead to foam cell formation more efficiently than
oxLDL alone.
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During incubation of macrophages with 100 ,....g/mL of oxLDL or oxLDL-IC
prepared with either human oxLDL antibodies or rabbit anti-human LDLhyperimmune serum (Figure 16), we observed.an increase in intracellular
cholesterol accumulation in cells incubated with free or complexed oxLDL,
supporting the atherogenic potential of oxLDL. Although oxLDL alone is capable
of causing foam cell formation, as attested by the 2-fold increase in intracellular
total cholesterol and 8-fold increase in CE, these data indicate a more profound
enhancement in intracellular cholesterol accumulation in macro phages incubated
with oxLDL-IC. Cells incubated with homologous oxLDL-IC prepared with
purified human oxLDL antibodies and oxLDL nearly doubled the intracellular
cholesterol levels observed in those incubated with oxLDL alone, and showed a
3-fold increase in CE, closely approaching the lipid accumulation observed in
cells incubated with heterologous oxLDL-IC prepared with anti-human LDLhyperimmune rabbit serum and oxLDL. Taken together, these data strongly
suggest that oxLDL-IC prepared with human oxLDL antibodies produce similar
results to those observed when using heterologous LDL-IC prepared with LDLhyperimmune rabbit serum. More importantly, we have shown for the first time
that the oxLDL-IC likely to be encountered in humans are have more atherogenic
potential than oxLDL alone.
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Figure 16. Cholesterol mass (J..Ig/mg cell protein) in THP-1 cells incubated with
for 48 hours with SFM (n=16), 100 ~g oxLDL (n=10), 100 IJg human oxLDL-IC
(H-IC) (n=28), or 100 J,Jg rabbit oxLDL-IC (R-IC) (n=12), that had been
precipitated by incubation with 4% PEG (18 hr, 4°C). The results are expressed
as mean of 4-7 experiments with samples run in duplicate or triplicate in each
experiment.
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Part 3: Conclusions
It is well known that the accumulation of CE in macrophages, and subsequent
transformation into foam cells, is enhanced by incubation of these cells with
modified forms of LDL (Brown et aI., 1980) and that incubation of macrophages
with heterologous LDL-IC prepared with human LDL and anti-human LDLhyperimmune rabbit sera drives intracellular CE accumulation more efficiently
than incubation with modified LDL ·alone (Griffith-et aI., 1988; Lopes-VirelJa et aI.,
1997a; Lopes-VirelJa et aI., 1997b; Virella et aI., 1995). Furthermore, Klimovet
al. (Klimov et aI., 1988) demonstrated that lipoprotein-antibody autoimmune
complexes isolated from human serum using sucrose density gradient
ultracentrifugation induced an approximate 3-fold CE increase in murine
macrophages when compared to the same cells incubated with lipoprotein alone.
Concurrently with the work of Klimov, data from our group strongly implicated the
participation of Fc-y receptors in LDL-IC uptake by macrophages by
demonstrating decreased CE accumulation in cells whose Fc-y receptors were
blocked (Griffith et aI., 1988), and we later proved that the receptors primarily
involved in this process were FcyRI (Lopes-VirelJa et aI., 1997a). Unfortunately,
these studies, though they convincingly showed ·that LDL-IC lead to CE
accumulation in macrophages, could be criticized by the fact that some authors
used macrophages isolated from non-human sources (Klimov et aI., 1988), while
others used LDL-IC prepared with LDL antibodies from a different species
(Griffith et aI., 1988; Lopes-Virella et aI., 1997a), or used human LDL-IC ·whose
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constituent components were not well.defined (Klimov et aI., 1988). Some of the
problems presented by these design flaws are obvious, while others are less
obvious.. First, with regard to the type of,macrophages used, non-human
macrophages may, or may not accurately reflect their human counterpart.
Though these cell lines are cultivated more easily than native human monocytederived macrophages, there may well be species to species differences,
therefore, human macrophages are obviously preferred. Second, using
heterologous LDL-IC prepared with LDL-hyperimmune rabbit sera and human
LDL may be problematic. Since rabbit antibodies are of higher avidity than
human LDL antibodies (Mironova et aI., 1996) and recognize a wider range of
epitopes on LOL, they form insoluble LDL-IC. Since the corresponding
homologous LDL-IC are soluble, one cannot be sure that macrophages
incubated with these heterologous LDL-IC complexes react Similarly to those
incubated with homologous LDL-IC. Third, data produced showing CE
accumulation in macrophages incubated with LDL-IC isolated from human sera
(Klimov et ai., 1988) are difficult to interpret because the type of antigen involved,
as well as the antibodies involved in the formation of these complexes is
unknown. These studies inadequately answer the question of what type of LDL
modification (glycation, oxidation, advanced glycated end products, etc.) drives
antibody formation and, therefore, fail to identify and/or characterize the type of
LOL-IC involved. Finally, the use of native LDL as a negative control may not be
the best choice as a baseline measurement for several reasons. It is common
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knowledge that LDL becomes atherogenic only after it is modified (Steinberg and
Witztum, 1999), that this modification confers immunogenicity (Steinbrecher et
aI., 1984a), and that LDL-IC are much more efficient than native LDL in their
abilityto cause foam cell formation in macrophages (Griffith et at, 1988; Klimov
et aI., 1988; Lopes-Virella and Virella, 1998). Since native LDL is not
immunogenic, and does not participate in formation of immune complexes, it
seems reasona.ble to suggest that a modified form of LDL known to participate in
formation of LDL-IC is a better control in these experiments.

In the present study, we are the first to report the successful in vitro production
and purification of human homologous oxLDL-IC, using oxLDL and oxLDL
antibodies isolated from human serum (Figure 14). OxLDL was chosen as the
antigen for this group of experiments because it occurs in vivo and has been
observed in foam cells and atherosclerotic plaques (ltabe et aI., 1994; Lee and
Kim, 1998; Magil, 1999; Palinski et aI., 1995; Palinski and Witztum, 2000;
Steinberg et aI., 1989). We then embarked on a series of experiments aimed at
overcoming the afore mentioned potential problems encountered by using
heterologous LDL-IC by using human monocyte-derived THP-1 macrophages
incubated with homologous oxLDL-IC, and used oxLDL as our baseline control,
rather than native LDL alone. We observed an accumulation of cholesterol
esters when human monocyte-derived THP-1 macro phages were incubated with
homologous oxLDL-IC that approached levels observed in macrophages
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incubated with oxLDL-IC prepared with anti-human LDL-hyperimmune rabbit
sera (Figure 16). Furthermore, this accumulation of cholesterol esters was
consistently higher than that observed in macrophages incubated with oxLDL
alone (Figure 15), with cholesterol ester concentrations ranging from 3 to 6-fold
higher than those observed in cells incubated with oxLDL alone.

In summary, these data provide conclusive evidence that homologous oxLDL-IC
prepared with human oxLDL and purified human oxLDL antibodies are actively
ingested by macrophages. Moreover, when homologous oxLDL-IC are
incubated with human monocyte-derived THP-1 macrophages, they appear to
result in transformation of these cells into foam cells, approaching the efficiency
observed in earlier studies where macro phages were incubated with
heterologous LDL-IC (Gisinger and Lopes-Virella, 1992; Griffith et aI., 1988;
Klimov et aI., 1985; Lopes-Virella at aI., 1997b). Together, these data
demonstrate that homologous oxLDL-ICnot only cause cholesterol and
cholesteryl ester accumulation in macrophages, but also are significantly more
efficient in their atherogenic potential than oxLDL alone. These observations
support the hypothesis presented by Lopes-Virella et al. that oxidized LDLcontaining immune complexes (oxLDL-IC) are active participants in foam cell
formation and atherosclerosis (Lopes-Virella and Virella, 1998). Moreover, these
data support the continued use of heterologous LDL-IC, prepared with human
LDL and LDL-hyperimmune rabbit serum, in studies of the effects of LDL-IC on
human monocyte-derived macrophages, foam cell formation, and atherogenesis.
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Chapter V

Summary and Conclusions
Patients with diabetes mellitus tend to develop a multitude of microvascular and
macrovascular complications, with heart disease" being the number one cause of
death in diabetes (Breyer, 1992; CDC, 1999; Cooper et aI., 1997; Kamanna et
aI., 1997; Lloyd etal., 1996; Maseretal., 1991; Nathan, 1993; NCHS/CDC,
2000; Orchardet aI., 1990). Accruing evidence suggests that two major vascular
complications of diabetes, nephropathy and atherosclerosis, may share
pathogenic mechanisms (Figure 17), with nephropathy involving mainly small
vessels (capillaries, arterioles, and small arteries), while atherosclerosis is
primarily a disease of large arteries (Diamond, 1991; Hirano, 1999; Kamanna et
aI., 1997; Moorhead et aI., 1997). Although diabetes is a well-defined risk factor
for atherosclerosis and nephropathy, the mechanisms responsible for lesion
pathogenesis in these subjects are multifaceted and have not been totally
defined. However, given the fact that glycated proteins are commonly formed in
subjects with diabetes and that glycated proteins are more susceptible to
oxidation (Mullarkey et ai., 1990; Nathan, 1996; Wolff, 1987), it is not surprising
that investigations of the role of modified proteins and lipoproteins in vascular
disease pathogenesis have been intense. Two key participants in
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atherosclerosis and nephropathy that have received considerable attention are
oxLDL and foam cells (Itabe et aI., 1994; Kamanna et aI., 1997; Kreisberg, 1998;
Lopes-Virella and Virella, 1998; Magil, 1999; Palinski and Witztum, 2000;
Shiozawa, 2000), with the altered metabolism of diabetes believed to be
responsible for increased oxidant stress and subsequent oxidation of LDL
(Brownlee et aI., 1984; Cooper et aI., 1997; Hunt et al., 1993; Lopes-Virella and
Virella, 1998; Mullarkey et aI., 1990; Wolff, 1987). Mechanisms by which oxLDL
may contribute to atherosclerosis and glomerulosclerosis are numerous. OxLDL
is chemotactic for monocytes, and is ingested by monocyte-derived
macrophages via scavenger receptors, bypassing the normal negative feedback
regulatory loop observed when native LDL is ingested via the LDL receptors. As
a result, oxLDL leads to foam cell formation, a prominent feature of both
atherosclerosis and glomerulosclerosis (Diamond, 1991; Lopes-Virella and
Virella, 1998; Magil, 1999; Parthasarathy et aI., 1986; Steinberg and Witztum,
1999).

In addition to the well-demonstrated ability of oxLDL to induce the transformation
of macro phages into foam cells, it has also been shown to be cytotoxic to
vascular endothelial cells, thus able to damage the endothelium and contribute
to the progression of atherosclerosis (Cathcart et aI., 1985; Morel et aI., 1984).
Macrophages may, in tum, contribute to the oxidation of LDL by generating free
radicals or through the myeloperoxidase pathway (Heinecke, 1998; Hunt and
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Wolff, 19911). In addition, macro phages are likely to promote atherosclerosis
and glomerulosclerosis by secreting various potent cytokines that profoundly
influence other vascular cells, including endothelial cells and T cells (Hansson,
1997; Schreiner, 1991; Terkeltaub et aI., 1998). Macrophages further contribute
to atherosclerotic lesion expansion by secreting transforming growth factor~,

which causes expansion of the extracellular matrix by upregulating production

of fibronectin, collagen, and proteoglycan synthesis (Berliner et aI., 1990). In
both atherosclerosis and glomerulosclerosis, fibrosis probably continues
independently of the initial stimulus.

Many groups researching this area have devoted their efforts to dissecting the
effects of oxLDL in atherogenesis and glomerulosclerosis (Berliner et aI., 1990;
Diamond, 1991; Guijarro and Keane, 1994; Haberland et aI., 1982; Haberland et
aI., 1988; Heinecke, 1998; Hirano, 1999; Jeng et aI., 1993; Kamanna et aI.,
1999; Maggi, 1994; Moorhead et aI., 1997), but there is also solid evidence that
oxLDL is immunogenic, supported by numerous reports of detectable antibodies
to oxLDL and MDA-LDL (an epitope of oxLDL) in human sera by a variety of
research groups, including our own (Bellazzi et aI., 1993; Bergmark et aI., 1995;
Korpinen et aI., 1997; Lopes-Virella et aI., 1999; Maggi, 1994; Salmon et aI.,
1987; Salonen et aI., 1992; Virella et at., 2000; Virella et aI., 1993). Furthermore,
support for a pathogenic role for LDL autoantibodies comes from the
observations of researchers showing that LDL-containing
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Figure 17. Analogies of atherosclerosis and glomerulosclerosis. Both
processes are triggered by endothelial insult, followed by an influx of monocytes.
The monocytes then transform into lipid-laden macrophages (foam cells), and
appear to secrete a variety of pro-inflammatory products, thus causing further
endothelial insult. As the disease progresses, there is smooth muscle cell or
mesangial cell expansion in atherosclerosis and glomerulosclerosis, respectively,
along with expansion of the extracellular matrix. Left unimpeded, complications
arise. (Diamond, 1991; Nathan, 1987).
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isolated from human serum can induce intracellular accumulation of cholesterol
esters (Gisinger and Lopes-Virella, 1992; Gisinger et aI., 1991; Griffith et aI.,
1988; Klimovet aI., 1985; Klimov et aI., 1988; Lopes-Virella et aI., 1991; Tertov
etal., 1990a; Virella et aI., 1995). Our group has pioneered research in this
area, focusing on the active role of antibodies to modified forms of LDL and the
LDL-immune complexes (LDL-IC) they form in atherogenesis and diabetes
(Lopes-Virella et aI., 1996; Lopes-Virella et al.~ 1997b; Lopes-Virella and Virella,
1998; Virella et aI., 1995). Subsequently, we have convincingly demonstrated
the atherogenic potential of heterologous oxLDL-IC prepared with human oxLDL
and anti-human LDL-hyperimmune rabbit serum (Gisinger and Lopes-Virella,
1992; Gisinger et al., 1991; Griffith et aI., 1988; Lopes-Virella et aI., 1991). Our

in vitro studies have shown that stimulation of human monocyte-derived
macrophages with insoluble heterologous LDL-IC led to an unparalleled
transformation of these cells into foam cells (Griffith et aI., 1988), as well as their
activation (Virella et aI., 1995). These observations documented that exposure
of human macrophages to LDL-IC led to increased uptake and impaired
degradation of LDL (Lopes-Virella et aI., 1991), along with enhancement of a
variety of cellular functions, including the release of pro-inflammatory cytokines
such as interleukin-1 ~ and tumor necrosis factor (TNF) (Virella et aI., 1995).
These activated macrophages can have pathological significance in that the
secreted cytokines contribute to vascular injury by upregulating the expression of
adhesion molecules, thus increasing the adherence of leukocytes to the
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endothelial cells (Lopes-VirelJa et aI., 1982) and promoting their migration into
the subendothelial space. Further substantiating the activation of macrophages
by LDL-IC, we demonstrated the ability of LDL-IC to cause respiratory burst in
human macrophages (Virella et aI., 1995).

The observations described above strongly suggest that modulation of the
immune system plays an important role in the pathogenesis of atherosclerosis
and glomerulosclerosis, and prompted us to further characterize the involvement
of LDL-IC and macrophages in these processes. Our studies were roughly
divided into three aims. We sought to 1) characterize of free and immune
complex-bound oxLDL antibodies; 2) determine if LDL-IC were associated with
nephropathy, as is the case with atherosclerosis; and 3) determine the
atherogenicity of homologous oxLDL-IC prepared with human oxLDL and
purified human anti-oxLDL antibodies.

The in-depth characterization of human oxLDL antibodies reported in this
dissertation was a complex process that required the isolation and purification of
both soluble (free) and immunocomplexed (bound) oxLDL antibodies from
serum. OxLDL antibodies isolated from both serum and LDL-IC were
predominantly IgG (primarily subclasses IgG1 and IgG3), followed by IgM and
minute levels of IgA. These IgG subclasses are known to activate phagocytic
cells and, the complement system, therefore, their presence in LDL-IC supports a
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proinflammatory role in atherosclerosis and glomerulosclerosis. We also
observed that the avidity of oxLDL antibodies isolated from immune complexes
was significantly higher than the avidity of unbound antibodies of the same
specificity isolated from serum, suggesting that there is a threshold of antibody
avidity required for the formation of stable LDL-IC, and that antibodies of oxLDL
are of sufficiently high avidity to form stable IC. Antibodies of lower avidity
remain in the circulation and are probably non-pathogenic. Collectively, these
findings indicate a possible pathogenic role for oxLDL antibodies and the oxLDLIC they·help form. These observations, furthermore, indicate that LDL-IC
formation may help explain the discrepant association of oxLDL antibody levels
and atherosclerosis/glomerulosclerosis. Indeed, it is reasonable to expect that
these Ie concentrations may have a stronger correlation with vascular disease
than that of oxLDL antibody levels alone.

With regard to the second undertaking of this research project, three
observations sparked our interest, causing us to investigate if LDL-containing
immune complexes were associated with diabetic nephropathy. First, our
literature review revealed that diabetes dramatically increases an individual's risk
for all types of vascular disease (Cooper et aI., 1997; Nathan, 1993). Although
there is little doubt that a positive relationship between hyperglycemia and
microvascular disease exists, hyperglycemia alone is not sufficient to cause the
observed pathology (Raptis and Viberti, 2001; Wolff, 1987). Second,' it has been

109

successfully argued that glomerulosclerosis, the root cause of diabetic
nephropathy, is an

~nalogous

proce.ss to atherosclerosis (Diamond, 1991;

Diamond, 1994; Moorhead et aI., 1997); with oxLDL and foam cells actively
participating in the development of diabetic nephropathy (Jeng et al., 1993;
Kamanna et aI., 1999; Kamanna et aI., 1996; Magil, 1999; Suzuki et aI., 2001),
as well as in atherosclerosis (Lopes-Virella and Virella, 1998). Third, an active
involvement of LDL-IC in atherosclerosis is supported by in vitro observations of
the conversion of monocyte-derived macrophages into foam cells by LDL-IC, the
activation and release of proinflammatory cytokines by macrophages incubated
with LDL-IC, and demonstration of a positive correlation between clinical
manifestations of atherosclerosis and LDL-IC levels in subjects with diabetes
(Lopes-Virella et aI., 1997b; Orchard et aI., 1999).

If atherosclerosis and glomerulosclerosis are indeed analogous processes, and
LDL-IC are active participants in atherosclerosis, we hypothesized that a similar
positive correlation would exist between nephropathy and LDL-IC. This was
indeed the case. When we compared various components of LDL-IC, including
LDL surrogate-markers such as cholesterol and apolipoprotein B (apoB), along
with free and Ie-bound oxLDL antibodies in diabetic subjects with varying
degrees of nephropathy, we made several interesting discoveries. Our analysis
of PEG-precipitated soluble immune complexes for LDL surrogate markers,
cholesterol and apoS, showed a positive correlation between urine albumin
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excretion (an indicator of the severity of nephropathy) and LDL-IC. Additionally,
we isolated oxLDL antibodies from the PEG-precipitated immune complexes.
Although PEG precipitates immune complexes irrespective of the
antigen/antibody composition, the isolation of oxLDL antibodies from

Ie that also

contained apaB and cholesterol firmly established the presence of oxLDL-IC as
components of these complexes. Lastly, we demonstrated that the avidity of
oxLDL antibodies isolated from PEG-precipitated immune complexes was higher
in immune complexes isolated from subjects with advanced nephropathy
(macroalbuminuria), compared to those with no detectable nephropathy
(normoalbuminuria), suggesting that the stability of oxLDL-IC may playa role in
nephropathy.

Although these findings may be interpreted to suggest that oxLDL-IC actively
participate in the pathogenesis of both atherosclerosis and glomerulosclerosis,
we fully realize that mere association does not equal causation. However, data
obtained in a small cohort of type 1 diabetic subjects (n=98), the Pittsburgh
Epidemiology Study of Complications, strongly favors a causal effect of LDL-IC
in atherosclerosis since the elevation of LDL-IC preceded the appearance of
CHD (Lopes-Virella et aI., 1997b; Orchard et ai., 1999). In fact, the baseline
levels of LDL-IC obtained at the beginning of the study, when the patients were
free of macrovascular disease, were significantly higher in the group that
eventually developed macrovascular complications than in a matched case-
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control grou·p who did not deveJop macrovasculardisease. These data require
confirmation via large-scale prospective studies of this type, wherein markers of
LDL.. IC are quantitated in the sera of subjects destined to progress to
nephropathy, or other measurable indicators of vascular disease. If these
markers are found to be present at increased levels compared to nonprogressors, the causative role of LDL-IC in the vascular disease of interest will
be strengthened .

. Turning to our third goal, we wished to address the issue of whether or not
. homologous oxLDL-IC, made with human oxLDL and purified human oxLDL
antibodies, would cause foam cell formation in human monocyte-derived.
macrophages, as had been observed using LDL-IC made with anti-human LDLhyperimmune rabbit serum (Gisinger et aI., 1991; Griffith et aI., 1988; LopesVirella et aI., 1991; Lopes-Virella and Virella, 1998). To accomplish this task, we
were able to draw upon the expertise within our group in the area of human
oxLDL antibody isolation (Mironova et aL, 1996; Virella et aI., 2000), and purified
relatively large quantities of oxLDL antibodies from human serum. Using these
antibodies, we developed a novel process for synthesizing and purifying human
homologous oxLDL-IC using a modification of Zubler's classical method of
soluble immune complex isolation, with 40/0 polyethylene glycol (Zubler et aI.,
1977). Upon isolation of immune complexes, we then co-incubated these
immune complexes with cells from the human monocyte-derived macrophage-
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like cell line, THP-1, and determined intracellular cholesterol and cholesteryl
ester accumulation. Our findings showed a massive intracellular accumulation of
cholesterol and cholesterol esters in THp... 1 cells incubated with homologous
human oxLDL-IC that was several fold higher than that of cells incubated with
oxLDL alone, and approached that of cells incubated with heterologous LDL-IC
made with hyperimmune rabbit sera. Added to this, parallel experiments carried
out by Koskinen and others in our group showed increased TNF expression in
THP-1 cells incubated with human red blood cells that had been coated with
oxLDL and purified oxLDL antibodies (unpublished data), strongly suggesting
that these Ie are capable of activating macrophages. These observations
strengthen the hypothesis that LDL-IC modulate the human immune system in a
proinflammatory manner, thus demonstrating the potential to exacerbate the
development -and progression of atherosclerosis (Lopes-Virella and Virella, 1998;
Lopes-Virella et aI., 1999). These observations are significant on several levels.
First, and foremost, these findings strongly implicate oxLDL-IC in the
pathogenesis of atherosclerosis and glomerulosclerosis. Second, these findings
validate the continued use of heterologous LDL-IC prepared with LDLhyperimmune rabbit sera in future studies of this nature. Third, this is the first
published report describing- preparation of human homologous oxLDL-IC, along
with its effect on human macro phages.

As is always the case, much work remains to be done. The mechanisms behind
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the accelerated development of vascular diseases such as atherosclerosis and
nephropathy in type 1 diabetes are poorly understood. Therefore, the definition
of predictors that could lead to the identification "of patients at risk for accelerated
development of atherosclerosis and/or nephropathy could represent a major
advancement in the treatment of these patients. If the levels or characteristics of
LDL-IC are proven to have such predictive power, simpler methods for their
identification can be developed . Patients identified by these predictors should
benefit from treatment with immunomodulators aimed at decreasi~g the
production of pathogenic LDL-IC.

Accordingly, the precise nature of the LDL modifications associated with the
synthesis of antibodies of sufficient avidity as to form stable LDL-IC that may be
proinflammatory, and thus contribute to both nephropathy and macrovascular
complications deserves investigation. Quantification of the various types of
naturally occurring LDL modifications in circulation will require raising antibodies
to these antigens, and the development of enzyme immunoassays (EIAs).
These EIAs can then be used to screen retrospectively for these modifications in
the baseline sera/Ie samples of patients from the DCCT cohort who either
developed atherosclerosis and/or nephropathy and a matched group of patients
who remained free of complications.. This data will be used to determine if high
concentrations of LDL-containing some of these modifications in the baseline
sera and/or IC are predictive of the development of nephropathy and/or
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atherosclerosis. Further studies designed are needed to characterize
immunogenic modifications of LDL (glycation, MDA-Iysine, AGE/ALE) and
determine if the presence of these modifications predict the development of
vascular complications are often ob.served in people with diabetes. Similarly, the
antibodies associated with these modified forms of LDL need to be characterized
by isotype and avidity to determine if a. specific subset is predictive of future
glomerulosclerotic or atherosclerotic pathology. The definition of such predictors
could lead to the identification of patients in which treatment with
immunomodulatory statins (Chen et aI., 2002) or stronger immunomodulators,
such as hydroxychloroquine (Wallace, 1996; Wallace et aI., 1993), would prevent
the development of micro- and macrovascular complications. Lastly, the
proinflammatory and atherogenic potential of LDL-IC formed between various
modifications of LDL and their corresponding antibodies needs to be tested in
vitro by incubating these LDL-IC with macro phages and mesangial cells and then
determining intracellular cholesterol and cholesterol ester accumulation, as well
as release of cytokines, specifically TNF, IL 1~, IL6 and GM-CSF.

In conclusion, diabetes mellitus is a disease associated with serious vascular
complications. And we have presented data suggesting that oxLDL-IC may play
a critical role in the pathogenesis of both microvascular and macrovascular
disease. Specifically, we are the first to report the positive association of oxLDLIC and diabetic glomerulosclerosis, and the design of a novel protocol for
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preparing purified homologous human oxLDL-IC. Additionally, we have reported
the results of a series of experiments that strongly implicate the ability of these
complexes to drive macrophage foam-cell transformation, a pathological
component of both atherosclerosis and glomerulosclerosis. These data form a
very strong body of evidence implicating oxLDL-IC as a culprit in vascular
disease, and present, for the first time, proof that IC formed from human oxLDL
and purified human oxLDL antibodies modulate this process in a negative
direction more so than oxLDL alone. At this point, these observations represent
the conceptual framework for on-going investigations that, if fruitful, promise to
illuminate new perspectives for prevention and intervention of both micro- and
macrovascular complications of diabetes mellitus.
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Appendix 1
Diabetes mellitus
Diabetes mellitus (DM), is a disorder of glucose metabolism that progressively
compromises the function of virtually every organ system in the human body
as its secondary complications inexorably develop (CDC, 1999; Nathan, 1993;
NCHS/CDC, 2000) (Table 1), and has the notoriety of being the fourth leading
cause of death by disease in the United States (Table 7). Diabetes is
characterized by hyperglycemia and affects approximately 15.7 million people
(or 5.9% of the population) in the United States, with an estimated economic
cost to our nation recently reaching $98 billion dollars per year (ADA, 1998).
Two major forms of diabetes, type I diabetes and type II diabetes, are
distinguished by the need for exogenous replacement of insulin. People with
type I diabetes, previously termed insulin-dependent diabetes mellitus (100M),
account for approximately 10 % of OM in the United States. This form of
diabetes usually appears abruptly before the age of 40, with typical symptoms
of thirst, excessive urination, increased appetite, rapid \",eight loss, and high
levels of sugar in the urine. In type I diabetes, there is destruction of the
pancreatic beta-cells in the islets of Langerhans, result!ng in an absolute
deficiency of the hormone, which necessitates exogenous insulin replacement
therapy. Type II diabetes, previously known as nO:1-insulin-dependent
diabetes mellitus (NIDDM), accounts for approxirnately 90% of DM in the
United States, and usually occurs gradually in peopie over the age of 40 who
are overweight. It is caused by a quantitative decrease in insulin production or
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Table 7. -Estimated number of deaths for the 10 leading causes of death:
United States, 2000 (NCHS/CDC, 2000)

Rank

Cause of death

Heart disease*
Cancer*
Stroke
3
Chronic lower respiratory disease*
5
Accidents
4
6
Diabetes*
Pneumoniallnfluenza
7
Alzheimer's Disease
8
Kidney disease*
9
10
Sel2ticemia
All causes
*Causes of death due to disease

1
2
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Total
number

Percentage
of deaths

709,894
551,833
166,028
123,550
93,592
68,662
67,024
49,044
37,672
31,613
1 ~898z912

38.0
29.6
8.9

6.6
5.0
3.7
3.6

2.6
2.0
1.7
100.0

or impaired insulin sensitivity, or a combination of th,:~

t-VV0.

l-he majority of

subjects afflicted with type II diabetes can be mana~E!d vlith diet and exercise
alone; however, when this approach fails, treatment \hfith oral hypoglycemic
agents or insulin is indicated (ADA, 2000).

OM complications.

Clearly, the quality of life for people with diabetes is diminished as a
consequence of increased lifetime risk for development of long-term vascular
complications including both microvascular disease (nephropathy, retinopathy,
and neuropathy) and macrovascular disease (atherosclerosis, ischaemic heart
disease, cerebrovascular disease, and peripheral vascular disease) (Breyer,
1992; Cooper et aI., 1997; Kamanna et aI., 1997; Lloyd et aI., 1996; LopesVirella and Virella, 1998; Maser et aI., 1991; Nathan, 1993; Orchard et aI., 1990;
Raskin, 1994). These complications mean that patients with diabetes are more
likely to have heart attacks, strokes, amputations, kidney failure, and blindness
than the general population; with accelerated and aggressive atherosclerosis
being the leading cause of morbidity and mortality in diabetes (Rubin et aI.,
1992)(Table 1 & 8).
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Table 8 •. Complications of diabetes in the United States (CDC, 1999;
NCHS/CDC, 2000)
Deaths
- Diabetes is the cause of an estimated 65,000 deaths among
Americans and is a contributing cause in another 95,000 deaths
annually.

Heart Disease and Stroke
- People with diabetes have a two to four-fold increase in heart disease
and are two to six times more likely to have a stroke than people who
do not have diabetes.

Kidney Disease
- Diabetes is the single most common cause of end-stage renal
disease (ESRD - where a person requires dialysis or a kidney
transplant to live).
- Thirty to forty percent of those with diabetes develop ESRD.
- Currently over one-third of all patients with ESRD have diabetes and
this number is expected to reach 500/0 if the current rate of increase
continues.

Blindness
- Diabetes is the leading cause of blindness among adults 20 to 74
years of age.

Amputations
- Diabetes is the underlying cause of the majority of leg and foot
amputations.
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Appendix 2.
Diabetic nephropathy: natural history without pharmacological
intervention.
For reasons that remain elusive, a significant percentage, but not all people with
diabetes develop diabetic nephropathy. Additionally, although the cumulative
incidence of nephropathy appears to be similar in both type I and type II diabetes
(Hasslacher et aI., 1989), nephropathy in type I diabetes tends to present in a
more homologous fashion than that in type II diabetes; therefore, this discussion
will focus primarily on un-arrested nephropathy in type I diabetes.

Nephropathy is recognized as one of the most severe metabolic components of
long-term diabetes (Nathan, 1996), with the lifetime risk of developing
nephropathy being approximately 30-400/0 for type I diabetes and 25-60% for
type II diabetes (Hasslacher et aI., 1989; Viberti et ai., 1992). If pharmacological
intervention with angiotensin-converting enzyme (ACE) inhibitors and
antihypertensives is not introduced early in the following timeline, all people
destined to develop diabetic nephropathy are expected to progress to end stage
renal disease (ESRD) through the various stages illustrated in figure 18 (Breyer,
1992; Mogensen et aI., 1983).

Early in the course of diabetes, the vast majority of affected people experience
functional changes in the kidney, such as hyperfiltration and trace amounts of
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albumin (referred to as microalbuminuria). If pharmacological intervention is not
instituted, renal morphological changes occur within the next few years. Seven
to 15 years after onset of diabetes, patients destined for nephropathy reach the
next stage, termed "incipient nephropathy." During this period, predictors of
diabetes-related nephropathy such as hyperfiltration, hypertension (HTN), poor
glycemic control, and microalbuminuria (urinary albumin excretion of 30-300
mg/day) occur. Approximately 17 years after the onset of type I diabetes,
macroalbuminuria (urinary albumin excretion of >300 mg/day) is manifested in
those 30-40% of type I diabetes patients destined to develop overt diabetic
nephropathy. Once these levels of albumin excretion are reached, renal function
inexorably declines, with 50% of patients reaching ESRD within 7 years of onset
of proteinuria. Ultimately, ESRD requires replacement of renal function using
dialysis or renal transplant.

What is common amongst all people with nephropathy is a high rate of
cardiovascular morbidity and mortality. In fact, myocardial infarction is
recognized as the leading cause of death in these patients (Degoulet et aI.,
1982; Wheeler, 1996). The mechanisms responsible for the increased
cardiovascular morbidity and mortality in this group of people remain somewhat
elusive, but are believed to involve the atherogenic lipid profile that commonly
accompanies nephropathy.
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INCIPIENT NEPHROPATHY

o

2

Predictors
*hyperfiltration
* microalbuminuria
* risi~g blood pressure
* poor glycemic control
5

Time (years)

HTN
11-23) 13-25

Onset of
~....;;:====

Diabet'es'

,

_____:.p~ro:t:e:in~u:r~i:a

Plasma
C rea tin ine

15-27

End Stage
R en a I
Disease

FUNCTIONAL CHANGES
STRUCTURAL CHANGES
\

ftGFR
Reversible albuminuria

11 Glomerular Basement Mambrane
Thickening

11 Kidney size

Mesangial Expansion

Figure 18. The natural history of nephropathy in type I diabetes without
pharmacological intervention (Breyer, 1992).
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Nephropathy and atherogenic lipids
Nephrotic hyperlipidemia is well documented. In 1860, Virchow first recorded its
presence in medical literature (Virchow, 1860), with his description of
degeneration in the kidneys of patients with Bright's disease; later Munk
introduced the term "lipid nephrosis" (Munk, 1916). In 1936, interstitial and
arterial "lipidosis" was described in people with diabetes (Kimmelsteil and
Wilson, 1936) and later, glomerular "lipidosis" was noted in intercapillary lesions
in diabetes (Wilens et aI., 1951). We now know that the albuminuria associated
with diabetic nephropathy is positively correlated with an atherogenic lipid profile
and macrovascular disease (Guijarro and Keane, 1994; Moorhead et aI., 1996;
Wheeler, 1996). Namely, albuminuria is associated with increasing blood levels
of total cholesterol, low-density lipoprotein (LOL) cholesterol, apolipoprotein S,
triglycerides, and reduced levels of high-density lipoprotein (HDL) cholesterol.
Whether these lipid abnormalities are a cause, a consequence, or an
epiphenomenona of diabetic nephropathy is unknown. However, it is known that
as plasma albumin levels decrease due to albuminuria, hepatocytes synthesize
excess amounts of very low density lipoprotein (VLDL) which is carried in the
circulation byapolipoprotein B (apo-B) (Moorhead, 1991). Once in the peripheral
circulation, lipases further reduce the VLDL to LDL. Paradoxically, as
nephropathy-related LDL synthesis increases there is an accompanying slower
than normal metabolism of LDL in the peripheral circulation (Warwick et aI.,
1990). The tumover rates of VLDL and LDL are slowed for reasons which
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include decreased activity of two enzymes, lipoprotein lipase (LPL) and lecithin
chole~terol

acyltransferase (LCAT). The reasons for the decreased enzyme

activity are unknown, but may be partly due to urinary loss of cofactors (Warwick
et aI., 1990). Nevertheless, plasma levels of LDL cholesterol are increased, thus
increasing the risk of cardiovascular disease.
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Appendix 3. ,.
Atherosclerosis.
Atherosclerosis is a multifactorial disease that has the notoriety of being
responsible for more than 500/0 of all mortality in developed nations, and is well
recognized as the primary contributor to the pathogenesis of heart attack, stroke,
and gangrene of the extremities (Ross, 1993). Various risk factors associated
with the disease are listed in table 9.

Atherosclerotic lesion formation is characterized by a gradual focal progressive
accumulation of cells, along with extracellular matrix and lipids in the intima of
mid-size to large arteries. Danger comes when the resulting lesion either
occludes the vessel or ruptures, thus triggering vascular occlusion via
thrombosis. The earliest morphological evidence of disease has been
appropriately termed the ''fatty streak" due to the accumulation of lipid-laden
macrophages and T lymphocytes within the innermost layer of the artery wall
(Faggiotto and Ross, 1984; Gerrity, 1981; Joris et aI., 1983). In 1973, Ross et at
formally proposed the response-to-injury hypothesis, suggesting that
atherosclerosis might be precipitated by one or more insults to the endothelial
lining of mid-size and large arteries (Ross and Glomset, 1973). This hypothesis
has been modified as more data have become available (Lopes-Virella et aI.,

1997b; Lopes-Virella and Virella, 1998; Ross, 1986; Ross, 1993; Steinberg,
1993).
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Table 9. Risk factors associated with atherosclerosis (American-HeartAssociation, 2001)
Non-Modifiable
. - Family History
- Age
- Gender

Modifiable
- Diabetes
- Sedentary lifestyle
-Cigarette smoking
- Hypertension
- Hyperlipidemia
- Poor nutrition
- Obesity
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Events contributing to the formation .of atherosclerotic lesions, as proposed by
this hypothesis are as follows (Figure 19): The endothelium is injured. The
injury may be mechanical, most notably at branch points in the arterial tree due
to hypertension and/or shear stress; or it may be chemical, caused by oxidized
low density lipoproteins, for example. Alternatively, the injury may be
immunological, or due to viral or bacterial infection, or due to the effect of toxins.
Indeed, the etiology of atherogenic injury is not mutually exclusive and may well
be a combination of one or more of these insults. Nevertheless, after the initial
injury there is trapping of lipoproteins and increased adherence of circulating
monocytes and T lymphocytes to the damaged endothelium, followed by
migration of the monocytes into the subendothelial space. Once in the arterial
intima, the monocytes differentiate into macrophages, secrete pro-inflammatory
cytokines, release oxygen active radicals that contribute to oxidation of
sequestered lipoproteins, ingest and metabolize modified lipoproteins, and are
transformed into lipid-laden foam cells. The foam cells, along with smooth
muscle cells and T lymphocytes are primary components of the lesions
appropriately described as "fatty streaks". Left uninterrupted, the fatty streak
expands with alternating layers of smooth muscle cells and lipid-engorged
macrophages, forming more advanced fibro-fatty lesions, ultimately resulting in
formation of a fibrous plaque. At some point, perhaps as a consequence of
excessive release of matrix metalloproteinases by activated macrophages
(Huang et aI., 1999), the plaque may destabilize and rupture, triggering a
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thrombogenic episode that can either occlude the vessel or cause progression of
the atherosclerotic lesion. Foam cell formation is recognized as a key
component of atherosclerosis and, interestingly, is suspected to play an equally
important role in nephropathy (Diamond, 1991; Magil, 1999; Moorhead et aI.,
1997).
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Figure 19. The response to injury hypothesis, adapted from Ross, 1999 (Ross,
1999). . Atherosclerotic lesions arise in response to endothelial dysfunction that
is initiated by an injury to the endothelium. The trapping of lipoproteins follows
Endothelial injury and migration of monocytes into the subendothelial space,
where the monocytes transform into lipid engorged macrophages (foam cells),
establishing the lesion known as a fatty streak. Progression of this lesion results
in a lipid-rich plaque, which may later become unstable and rupture, triggering
blood clot formation.
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